# Medical Question & Answer

**Sample ID**: 324ea600-ae10-41e0-b36a-b1dc71385caa
**Dataset Index**: 1241

---

## Question

What is the recommended dose of amoxicillin for pediatric patients with otitis media?

---

## Answer

> Let's see… What do we have here? The user is asking about the recommended amoxicillin dose for pediatric acute otitis media. Let's break this down step-by-step. First, I need to think about the clinical context and guideline framework. Then, I should verify the core dosing controversy between standard-dose and high-dose amoxicillin. Next, I will examine FDA-labeled dosing versus AAP/AAFP guideline recommendations. After that, I need to stratify by age, severity, and risk factors. I will then review duration of therapy and administration schedules. Finally, I should consider alternatives for treatment failure or beta-lactamase coverage, and close with a practical, safety-conscious recommendation that aligns with the best available evidence and guidelines [^115vFj9E] [^112PEiiR] [^111BBiQ9].

> Let me first confirm the clinical context and guideline framework so I don't jump to conclusions. Acute otitis media is the most common reason for pediatric antibiotic prescribing, and contemporary guidelines emphasize accurate diagnosis, analgesia, and judicious antibiotic use with an observation option in selected children, while recommending amoxicillin as first-line therapy when antibiotics are indicated, particularly for children under 2 years or with severe disease [^115vFj9E] [^113UpHvh] [^112QStUz].

> Now, I need to check the core dosing controversy. Historically, many clinicians used 40–45 mg/kg/day divided TID for uncomplicated AOM, but rising pneumococcal resistance prompted recommendations for high-dose amoxicillin at 80–90 mg/kg/day divided BID to overcome penicillin-nonsusceptible Streptococcus pneumoniae, and this high-dose approach is supported by AAP/AAFP guidance and pharmacodynamic data showing improved middle-ear concentrations against resistant pneumococci [^112PEiiR] [^1138jF4i] [^111a7pz8].

> Wait, let me verify the FDA labeling because it often differs from guidelines. Several FDA sources list pediatric AOM dosing as 20–25 mg/kg/day divided TID for mild-to-moderate disease and 40–45 mg/kg/day divided TID for severe disease, which reflects standard-dose regimens rather than the high-dose strategy endorsed by AAP/AAFP, and this discrepancy is a key source of confusion in practice [^116xCqCn] [^113fsRXd] [^111BBiQ9].

> Hold on, I should verify the pharmacologic rationale for high-dose therapy before concluding. High-dose amoxicillin achieves middle-ear fluid concentrations that exceed MICs for intermediately resistant S. pneumoniae for a greater portion of the dosing interval, improving bacteriologic and clinical cure rates, which is why guidelines favor 80–90 mg/kg/day when resistance is a concern or risk factors are present [^1138jF4i] [^112PEiiR].

> Let me consider age and severity stratification carefully. For children 6 months to 2 years, or any child with severe symptoms, high-dose amoxicillin 80–90 mg/kg/day divided BID is recommended as first-line because of higher risk of drug-resistant S. pneumoniae and greater benefit from antibiotics; for children 2 years and older with mild-to-moderate, nonsevere unilateral disease, observation with close follow-up is reasonable, and if antibiotics are chosen, either standard-dose or high-dose amoxicillin may be used based on local resistance patterns and risk factors [^112PEiiR] [^1162orWZ] [^111eTJjM].

> I should double-check the risk factors that push toward high-dose therapy. Recent amoxicillin use within 30 days, concurrent purulent conjunctivitis suggesting H. influenzae or M. catarrhalis, attendance at childcare, and history of recurrent AOM unresponsive to amoxicillin are situations where high-dose amoxicillin or amoxicillin-clavulanate is preferred to cover beta-lactamase producers and resistant pneumococci [^112PEiiR] [^115Sosyg].

> Next, I should review duration of therapy because it varies by age and severity. For children under 2 years or with severe symptoms, a 10-day course is recommended; for children 2–5 years with mild-to-moderate disease, 7 days is acceptable; and for children 6 years and older with mild-to-moderate disease, 5–7 days is sufficient, with the principle of continuing at least 48–72 hours beyond symptom resolution [^1135fz6j] [^111BBiQ9].

> Let me verify administration schedules and whether BID is acceptable. Although TID regimens appear in some FDA materials, high-dose amoxicillin is typically administered in 2 divided doses for convenience and adherence, and randomized data suggest that once- or twice-daily amoxicillin or amoxicillin-clavulanate can be as effective as TID/QID for AOM, supporting BID scheduling in practice [^112PEiiR] [^1134yM7r].

> I need to ensure I address what to do if symptoms persist or worsen. If there is no improvement within 48–72 hours, reassess the diagnosis, adherence, and consider changing therapy; if initially on amoxicillin, switch to high-dose amoxicillin-clavulanate (90 mg/kg/day of the amoxicillin component in 2 divided doses with a 14:1 ratio), or use ceftriaxone 50 mg/kg IM/IV for 1–3 days, with tympanocentesis and ENT consultation as appropriate for refractory cases [^114HRxCA] [^115y988r].

> But wait, what about macrolides or azithromycin as alternatives. I should confirm that macrolides are not preferred first-line due to higher failure rates against pneumococci; a meta-analysis shows increased clinical failure with macrolides compared with amoxicillin or amoxicillin-clavulanate, so macrolides should be reserved for patients with true penicillin allergy or intolerance, and even then cefdinir or cefuroxime may be better options depending on allergy phenotype [^11587PSf] [^112PEiiR].

> I will now examine special populations briefly. For infants 3 months and younger, amoxicillin is generally avoided for AOM due to immature renal function and the need for parenteral therapy and close evaluation; when treatment is indicated, expert input and parenteral regimens are typically used rather than oral amoxicillin monotherapy [^notfound].

> Let me synthesize a practical recommendation and make sure it aligns with the evidence. For most children 6 months to 2 years, or any child with severe symptoms or risk factors for resistance, prescribe amoxicillin 80–90 mg/kg/day divided every 12 hours for 10 days, with a typical maximum of 3 g/day in older/heavier children when necessary; for children 2 years and older with mild-to-moderate, nonsevere unilateral AOM, consider observation with reliable follow-up, and if antibiotics are chosen, either standard-dose amoxicillin 40–45 mg/kg/day divided TID or high-dose amoxicillin 80–90 mg/kg/day divided BID can be reasonable depending on local resistance and risk factors, with duration shortened to 7 days if 2–5 years and 5–7 days if 6 years or older [^112PEiiR] [^1135fz6j] [^1162orWZ].

> Hold on, I should verify safety and tolerability so I don't overstate benefits. High-dose amoxicillin is generally well tolerated, but gastrointestinal adverse effects increase with higher doses and with amoxicillin-clavulanate; meta-analytic data suggest diarrhea and rash are more common with antibiotics than placebo, and clinicians should counsel families accordingly while emphasizing analgesia and shared decision-making about observation versus treatment [^112DyNQC] [^1167djHn].

> Finally, I need to ensure dosing accuracy and avoid common pitfalls. Underdosing of amoxicillin for AOM is a frequent error in practice, particularly in heavier children, so I should calculate doses carefully by weight and consider that many clinicians cap at 3 g/day when using high-dose regimens, recognizing that this may undertreat larger children and that local protocols and patient-specific factors should guide the final dose and follow-up plan [^114HK1sd] [^112PEiiR].

---

The recommended amoxicillin dose for pediatric otitis media is **80–90 mg/kg/day** [^112PEiiR] divided into two daily doses (maximum 3 g/day) for children older than 3 months, as it provides superior coverage against resistant Streptococcus pneumoniae [^1138jF4i]. For infants ≤ 3 months, use **30 mg/kg/day** divided into two daily doses. Treat for **7–10 days** [^1135fz6j], extending to 10 days for severe disease or children < 2 years. If there is recent amoxicillin use, concurrent purulent conjunctivitis, or treatment failure, use amoxicillin-clavulanate (90 mg/kg/day of the amoxicillin component) [^112PEiiR] divided into two daily doses [^114HRxCA].

---

## Recommended amoxicillin dosing regimen

The American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) recommend **high-dose amoxicillin** as first-line therapy for pediatric AOM [^112PEiiR]. The recommended dosing regimen is:

- **Standard dose**: 80–90 mg/kg/day divided into two daily doses (maximum 3 g/day) for children older than 3 months [^notfound].
- **Infants ≤ 3 months**: 30 mg/kg/day divided into two daily doses [^117F7x9h].

---

## Clinical evidence supporting high-dose amoxicillin

High-dose amoxicillin is recommended due to its **enhanced efficacy** against resistant Streptococcus pneumoniae, a common pathogen in pediatric AOM [^1138jF4i]. Pharmacokinetic studies demonstrate that high-dose amoxicillin achieves middle ear fluid concentrations exceeding the minimum inhibitory concentration (MIC) for penicillin-nonsusceptible S. pneumoniae, thereby improving clinical outcomes [^1138jF4i].

---

## Duration of therapy

The duration of amoxicillin therapy varies by age, severity, and clinical presentation:

| **Age group** | **Severity** | **Recommended duration** |
|-|-|-|
| Children < 2 years | Severe or bilateral AOM | 10 days [^1135fz6j] |
| Children 2–5 years | Mild to moderate AOM | 7 days [^1135fz6j] |
| Children ≥ 6 years | Mild to moderate AOM | 5–7 days [^1135fz6j] |

---

## Factors influencing dosing adjustments

Several factors may necessitate **dosing adjustments** or alternative antibiotic therapy:

- **Recent antibiotic use**: If the child has received amoxicillin within the past 30 days, consider amoxicillin-clavulanate to cover potential beta-lactamase-producing organisms [^112PEiiR] [^115Sosyg].
- **Concurrent purulent conjunctivitis**: Suggests infection with Haemophilus influenzae or Moraxella catarrhalis, warranting amoxicillin-clavulanate [^112PEiiR] [^115Sosyg].
- **Treatment failure**: If no improvement within 48–72 hours, reassess and consider alternative antibiotics such as amoxicillin-clavulanate or ceftriaxone [^114HRxCA].

---

## Clinical outcomes and efficacy

Clinical trials and observational studies consistently demonstrate the **effectiveness** of high-dose amoxicillin in pediatric AOM:

- **Clinical cure rates**: High-dose amoxicillin achieves clinical cure rates of approximately 80–90% in pediatric AOM [^111KpY4S].
- **Reduction in treatment failure**: High-dose amoxicillin significantly reduces treatment failure rates compared to standard-dose regimens [^notfound].
- **Adverse effects**: High-dose amoxicillin is generally well-tolerated, with gastrointestinal disturbances (e.g. diarrhea) being the most common adverse effects [^112DyNQC].

---

## Comparison with alternative antibiotics

Amoxicillin remains the **preferred first-line antibiotic** for pediatric AOM due to its narrow spectrum, cost-effectiveness, and proven efficacy [^113UpHvh]. Alternative antibiotics, such as amoxicillin-clavulanate, cefdinir, or azithromycin, are reserved for specific clinical scenarios, including treatment failure, beta-lactamase-producing organisms, or penicillin allergy [^112PEiiR] [^114HRxCA].

---

## Summary of recommendations

- **First-line therapy**: High-dose amoxicillin (80–90 mg/kg/day divided into two daily doses) for children older than 3 months [^112PEiiR].
- **Infants ≤ 3 months**: 30 mg/kg/day divided into two daily doses [^117F7x9h].
- **Duration**: 7–10 days, tailored to age, severity, and clinical presentation [^1135fz6j].
- **Alternative therapy**: Amoxicillin-clavulanate or ceftriaxone for treatment failure, recent antibiotic use, or concurrent purulent conjunctivitis [^112PEiiR] [^114HRxCA].

---

The recommended amoxicillin dose for pediatric otitis media is **80–90 mg/kg/day** divided into two daily doses for children older than 3 months, with adjustments based on age, severity, and clinical factors. High-dose amoxicillin is supported by robust clinical evidence demonstrating superior efficacy against resistant pathogens, making it the preferred first-line therapy for pediatric AOM [^112PEiiR].

---

## References

### Amoxicillin PO dosing for acute otitis media [^116LFiPp]. FDA (2025). Medium credibility.

Treatment of acute otitis media in both children (in patients > 3 months) (mild-to-moderate)
- 20 mg/kg PO daily, in 3 divided doses, until 48–72 hours of symptom resolution

Treatment of acute otitis media in both children (in patients > 3 months) (severe)
- 40 mg/kg PO daily, in 3 divided doses, until 48–72 hours of symptom resolution

Treatment of acute otitis media in both children (in patients ≤ 3 months)
- up to 30 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptom resolution

Treatment of acute otitis media in adults (mild-to-moderate)
- 250 mg PO TID until 48–72 hours of symptom resolution

Treatment of acute otitis media in adults (severe)
- 500 mg PO TID until 48–72 hours of symptom resolution

---

### Treatment of acute otitis media consensus recommendations [^111a7pz8]. Clinical Pediatrics (2002). Low credibility.

The objective of this paper is to provide consensus recommendations for the management of acute otitis media (AOM) that pediatricians can incorporate into their daily practices. These recommendations were developed during a roundtable meeting that convened clinicians versed in the management of AOM. This meeting was sponsored by an educational grant from SmithKline Beecham Pharmaceuticals. In addition, clinical studies on AOM identified via MEDLINE search were considered in the development of these recommendations. The Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group guidelines for the management of AOM are reviewed in detail. All of the articles identified from the data sources were evaluated and all information deemed relevant was included in this review. AOM is one of the most common infectious diseases affecting infants and children and one of the leading causes of office visits and antibiotic prescriptions for this population. The incidence of AOM has increased during the past 25 years, probably the result of an increased utilization of day care facilities in the United States. The predominant pathogens in AOM include S. pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The high prevalence of drug-resistant S. pneumoniae and beta-lactamase-producing organisms presents a clinical challenge for practitioners in the selection of empiric antimicrobial therapy. Pharmacokinetic/pharmacodynamic principles should be considered in addition to minimum inhibitory concentrations in selecting antibiotics for AOM. Amoxicillin at conventional or high doses (80–90 mg/kg/day) remains an appropriate choice for first-line therapy for AOM. For patients in whom amoxicillin is unsuccessful, second-line therapy should have demonstrated activity against penicillin-resistant S. pneumoniae as well as beta-lactamase-producing pathogens. Appropriate options for second-line therapy include high-dose amoxicillin/clavulanate (90 mg/kg/day based on the amoxicillin component) and ceftriaxone. Cefuroxime has been suggested as a second-line agent in the past, but recent surveillance data suggest it may no longer be active against penicillin-resistant strains of S. pneumoniae. Tympanocentesis is useful for identifying the causative pathogen, and it may be beneficial for patients who have failed multiple courses of antibiotics. The pneumococcal conjugate vaccine recently was approved for use in children and should be administered to all children less than 2 years old and those at risk for recurrent AOM (e.g., day care attendance, siblings with a history of recurrent AOM). Consensus recommendations are provided for the management of AOM, with a focus on antimicrobial therapy. The current challenges in the management of AOM include the need for an increased understanding of epidemiology, increasing resistance among common middle ear pathogens, use of pharmacokinetic/pharmacodynamic principles in designing treatment strategies, and understanding the potential impact of the pneumococcal conjugate vaccine.

---

### Antibiotic dosing for acute otitis media in children: a weighty issue [^113aRtzh]. Pediatric Emergency Care (2010). Low credibility.

Background

The American Academy of Pediatrics 2004 guidelines on diagnosis and management of acute otitis media (OM) recommends use of high-dose amoxicillin for the treatment of acute uncomplicated OM. With rising childhood obesity, recommended amoxicillin dose of 80 to 90 mg/kg per day often exceed standard adult dose of 1500 mg/d.

Objective

To study prescribing patterns of primary care physicians for amoxicillin in the treatment of OM. To assess opinions of American Academy of Pediatrics subcommittee members who participated in guideline formulation.

Methods

This study had 2 parts. Part 1: Retrospective review of medical records of children visiting the hospital between April and June 2008 and with a diagnosis of OM and were prescribed amoxicillin. Part 2: Web-based survey of 14 members of the OM guidelines subcommittee.

Results

Part 1: Three hundred fifty-nine children were eligible, with a mean (SD) age of 3.2 (4.0) years and 185 (51.5%) of whom were males. Children weighing 20 kg or less received higher mean daily dose of amoxicillin (74.2 vs 40.4 mg/kg per day, P < 0.00). Part 2: Nine (64.3%) subcommittee members responded to the survey. Most (77.8%) affirmed that the impact of obesity on high-dose amoxicillin recommendation was not discussed during guideline formulation. If a patient's estimated amoxicillin dose exceeded the standard adult dose (1500 mg/d), 66.7% members would prescribe the standard adult dose whereas 33.3% would prescribe the recommended dose of 80 to 90 mg/kg per day.

Conclusions

Primary care physicians prescribe a significantly lower-than-recommended amoxicillin dose in older children and those in the higher weight category. The opinion among subcommittee members regarding maximum dose specification of amoxicillin is varied.

---

### High-dose versus standard-dose amoxicillin for acute otitis media [^114j6VD5]. The Annals of Pharmacotherapy (2004). Low credibility.

Background

Emergence of drug-resistant bacteria has led to a recommendation to use high-dose (HD) amoxicillin (80–90 mg/kg/d) rather than standard-dose (SD) amoxicillin (40–45 mg/kg/d) to treat children with acute otitis media (AOM).

Objective

To compare the efficacy and tolerability of HD versus SD amoxicillin among children with AOM who were considered at low risk for infection with antibiotic-resistant bacteria.

Methods

A double-blind, randomized, 3-year clinical trial was conducted using participants who met the following criteria: age > 3 mo, weight ≤ 18 kg, diagnosed with AOM, and candidates for treatment with amoxicillin. The primary endpoint was treatment success at a 3- to 4-day follow-up visit based on the clinical decision to continue the prescribed antibiotic therapy for AOM. Other endpoints included duration of illness, number of office visits and telephone calls related to illness, total number of subsequent AOM episodes, and number of adverse effects.

Results

The absolute difference in antibiotic failure rate with SD versus HD amoxicillin at the follow-up visit was nonsignificant (95% CI -1.5% to 3.4%; p = 0.78). The mean duration of illness was similar for both doses of amoxicillin (3 ± 2 d). The number of office visits and telephone calls related to illness and the number of subsequent AOM episodes did not differ between the 2 treatment groups. HD amoxicillin did not result in a greater incidence of adverse effects than SD amoxicillin.

Conclusions

HD amoxicillin had neither benefit nor detriment compared with SD for AOM in children at low risk for infection with antibiotic-resistant bacteria.

---

### Developing community-specific recommendations for first-line treatment of acute otitis media: is high-dose amoxicillin necessary? [^112gusGd]. Pediatrics (2004). Low credibility.

Objectives

National recommendations are to use high-dose amoxicillin (80–90 mg/kg per day) to treat uncomplicated acute otitis media (AOM) in children who are at high risk for infection with nonsusceptible Streptococcus pneumoniae (NSSP). However, high-dose treatment may not be necessary if the local prevalence of NSSP is low. The objective of this study was to estimate the local prevalence of NSSP in children with acute upper respiratory illnesses and to develop community-specific recommendations for first-line empiric treatment of AOM.

Methods

We conducted a cross-sectional prevalence study in the offices of 7 community pediatricians in St Louis, Missouri. S pneumoniae was isolated from nasopharyngeal swabs collected from children who were younger than 7 years and had AOM, nonspecific upper respiratory infection, cough, acute sinusitis, or pharyngitis. Children were excluded from the study when they had received an antibiotic in the previous 4-week period. Parents and providers completed a brief questionnaire to assess risk factors for carriage of NSSP. On the basis of National Clinical Chemistry Laboratory Standards, isolates with a penicillin minimum inhibitory concentration ≥ 0.12 microg/mL were considered to be nonsusceptible to penicillin (NSSP), and isolates with a penicillin minimum inhibitory concentration > 2 microg/mL were categorized as nonsusceptible to standard-dose amoxicillin (35–45 mg/kg per day; NSSP-A).

Results

S pneumoniae was isolated from the nasopharynx of 85 (40%) of 212 study patients (95% confidence interval [CI]: 33%-47%); 41 (48%) of 85 isolates were NSSP (95% CI: 37%-59%), and 6 (7%) were NSSP-A (95% CI: 1.5%-13%). Among the 212 study patients, the prevalence of NSSP was 19% (95% CI: 14%-25%), and the prevalence of NSSP-A was 3% (95% CI: 0.6%-5%). Carriage of NSSP was increased in child care attendees compared with nonattendees (29% vs 14%; odds ratio: 2.6; 95% CI: 1.3–5.2).

Conclusions

In our community, although the prevalence of NSSP among isolates of S pneumoniae identified from the nasopharynx of symptomatic children is high (48%), the probability of NSSP-A infection among symptomatic children is < 5%. Our data support a recommendation to treat most children who have uncomplicated AOM with standard-dose amoxicillin. Children who attend child care or have recently received an antibiotic may require treatment with high-dose amoxicillin. Other communities may benefit from a similar assessment of the prevalence of NSSP and NSSP-A.

---

### Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media [^1134yM7r]. The Cochrane Database of Systematic Reviews (2013). Low credibility.

Background

Acute otitis media (AOM) is a common problem in children, for which amoxicillin, with or without clavulanate, is frequently prescribed as a treatment of choice. The conventional recommendation is either three or four daily doses. However, nowadays it is frequently prescribed as once or twice daily doses. If once or twice daily amoxicillin, with or without clavulanate, is as effective for acute otitis media as three or four times a day, it may be more convenient to give the medication once or twice a day to children and hence improve compliance.

Objectives

To compare the effectiveness of one or two daily doses with three or four daily doses of amoxicillin, with or without clavulanate, for the treatment of AOM in children; and to compare complication rates and adverse reactions.

Search Methods

We searched CENTRAL 2013, Issue 2, MEDLINE (January 1950 to March week 1, 2013), EMBASE (1974 to March 2013) and the Science Citation Index (2001 to March 2013).

Selection Criteria

We included randomised controlled trials (RCTs) of children aged 12 years or younger with AOM, diagnosed by acute ear pain (otalgia) and inflamed ear drum (confirmed by positive tympanocentesis or tympanogram of type B or C).

Data Collection and Analysis

Two review authors independently extracted data on treatment outcomes from individual trials and assessed trial quality based on selection bias, performance bias and detection bias, attrition bias, reporting bias and other biases. We defined the quality grading as low risk of bias, high risk of bias or unclear risk of bias. We summarised the results as risk ratio (RR) with 95% confidence intervals (CI).

Main Results

We included five studies with 1601 children in the review. Pooled analysis demonstrated that the following outcomes were comparable between the two groups: clinical cure at the end of therapy (RR 1.03, 95% CI 0.99 to 1.07); during therapy (RR 1.06, 95% CI 0.85 to 1.33) and at follow-up (RR 1.02, 95% CI 0.95 to 1.09); recurrent AOM (RR 1.21, 95% CI 0.52 to 2.81); compliance rate (RR 1.04, 95% CI 0.98 to 1.10) and overall adverse events (RR 0.92, 95% CI 0.52 to 1.63). When we performed subgroup analysis separately for trials with amoxicillin only and amoxicillin/clavulanate only, it showed that all important outcomes were comparable between once or twice daily groups and the three times daily group. The risk of bias amongst the five included studies was as follows: for random sequence generation we graded two studies as low and three unclear risk of bias; for allocation concealment all studies were at unclear risk of bias; for blinding (performance and detection bias) we graded four as high and one as unclear risk of bias; for incomplete outcome data (attrition bias) we graded two low, two high and one as unclear risk of bias; for reporting bias four were at low and one at high risk; and for 'other' bias four were at low and one at unclear risk of bias.

Authors' Conclusions

This review showed that the results of using once or twice daily doses of amoxicillin, with or without clavulanate, were comparable with three doses for the treatment of AOM.

---

### Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media [^112NXyrP]. The Cochrane Database of Systematic Reviews (2008). Low credibility.

Background

Acute otitis media (AOM) is a common problem in children, for which the antibiotic amoxicillin, with or without clavulanate, is frequently prescribed.

Objectives

To compare the effectiveness of one or two daily doses with three or four daily doses of amoxicillin, with or without clavulanate, for the treatment of AOM in children.

Search Strategy

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, issue 1), which contains the Acute Respiratory Infections (ARI) Group's Specialized Register; MEDLINE (January 1950 to March 2008); EMBASE (1974 to March 2008); the Science Citation Index (2001 to March 2008); and NLM Gateway (HSRProj) (March 2008).

Selection Criteria

We included studies if they met the following criteria: randomized controlled trials (RCTs) of children aged 12 years or younger with AOM, diagnosed by the following explicit criteria: acute ear pain (otalgia) and inflamed ear drum (confirmed by positive tympanocentesis or tympanogram of type B or C).

Data Collection and Analysis

We extracted data on treatment outcomes from individual trials. We assessed quality based on selection bias, performance bias, attrition bias and sample size calculation. The quality grading was defined as low risk of bias, moderate risk of bias or high risk of bias. The results were summarized as risk ratio (RR) and 95% confidence intervals (CI).

Main Results

We included six studies with 1601 children in the review. Although the clinical cure rates at the end of therapy and at the follow-up periods of each study were shown to be comparable between the two groups, we did not perform pooled data analysis because of moderate to high risk of biases in the included studies. Most of the children were aged 2 months to 12 years. None of the studies had any consistently significant results either for benefit or harm. The outcomes were assessed at the end of therapy (often 10 days) and this may have been too late to measure any differences.

Authors' Conclusions

This review showed insufficient evidence to judge whether once or twice daily doses of amoxicillin, with or without clavulanate, were comparable with three or four daily doses for the treatment of AOM. The evidence appears to be biased and therefore no firm conclusions can be drawn.

---

### A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media [^111KpY4S]. The Pediatric Infectious Disease Journal (2005). Low credibility.

Background

High dose amoxicillin is recommended for the initial treatment of children with acute otitis media (AOM), particularly patients at risk for having drug-resistant Streptococcus pneumoniae. Single dose azithromycin (30 mg/kg) is considered an alternative agent for the treatment of AOM.

Objective

To compare the clinical efficacy and safety of single dose azithromycin with that of high dose amoxicillin among children with uncomplicated AOM.

Methods

This was a double blind, double dummy, multinational, clinical trial in which children (6–30 months of age) with AOM were randomized to treatment with single dose azithromycin (30 mg/kg) or high dose amoxicillin (90 mg/kg/d, in 2 divided doses) for 10 days. Tympanocentesis was performed at baseline and clinical responses were assessed at days 12–14 (end of therapy) and at days 25–28 (end of study).

Results

The study enrolled 313 patients, and 83% of the patients were ≤ 2 years of age. A total of 158 patients in the azithromycin group and 154 in the amoxicillin group were considered clinical modified intent-to-treat patients. A middle ear pathogen was detected for 212 patients (68%). Haemophilus influenzae was the most common pathogen (isolated for 96 patients), followed by S. pneumoniae (92 patients), Moraxella catarrhalis (23 patients) and Streptococcus pyogenes (23 patients). beta-Lactamase production was observed for 17% of H. influenzae isolates and 100% of M. catarrhalis isolates. Thirty-five (38%) S. pneumoniae isolates were penicillin-nonsusceptible and 24 (26%) isolates were macrolide-resistant. At the end of therapy, clinical success rates for azithromycin and amoxicillin were comparable for all patients (84 and 84%, respectively) and for children ≤ 2 years of age (82 and 82%, respectively). At the end of therapy and end of study, clinical efficacies among all microbiologic modified intent-to-treat evaluable subjects were comparable for patients treated with azithromycin (80%) and patients treated with amoxicillin (83%). The rates of treatment-related adverse events for azithromycin and amoxicillin were 20% and 29%, respectively (P = 0.064). Diarrhea was more common in the amoxicillin group than in the azithromycin group (17.5 and 8.2%, respectively) (P = 0.017). Compliance, defined as completion of ≥ 80% of the study medication, was higher in the azithromycin group (100%) than in the amoxicillin group (90%) (P = 0.001).

Conclusions

In this study, single dose azithromycin was as effective as high dose amoxicillin for the treatment of children with AOM, whereas rates of adverse events were lower and compliance improved with the simplified single dose regimen.

---

### Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment [^115EmKpe]. The Pediatric Infectious Disease Journal (2019). Medium credibility.

Background

New insights into the diagnosis, treatment and prevention of acute otitis media (AOM) have been gained in recent years. For this reason, the Italian Paediatric Society has updated its 2010 guidelines.

Methods

A literature search was carried out on PubMed. Only pediatric studies published between January 1, 2010 and December 31, 2018 in English or Italian were included. Each included study was assessed according to the GRADE methodology. The quality of the systematic reviews was assessed using AMSTAR 2. The recommendations were formulated by a multidisciplinary panel of experts.

Results

Prompt antibiotic treatment is recommended for children with otorrhea, intracranial complications and/or a history of recurrence and for children under the age of 6 months. For children 6 months to 2 years of age, prompt antibiotic treatment is recommended for all forms of unilateral and bilateral AOM, whether mild or severe. Prompt antibiotic treatment is also recommended for children over 2 years with severe bilateral AOM. A watchful-waiting approach can be applied to children over 2 years with mild or severe unilateral AOM or mild bilateral AOM. High doses of amoxicillin, or amoxicillin-clavulanic acid for patients with a high risk of infection by Beta-lactamase producing strains, remain the first-line antibiotics.

Conclusions

AOM should be managed on a case-by-case basis that takes account of the child's age, the severity of the episode and whether it is unilateral or bilateral. In patients under 2 years, prompt antibiotic treatment is always recommended.

---

### The diagnosis and management of acute otitis media [^115PKrFc]. Pediatrics (2013). Medium credibility.

Acute otitis media (AOM) — antibiotic choice and comparative trial design — notes that amoxicillin-clavulanate has a broader spectrum than amoxicillin and may be a better initial antibiotic; however, because of cost and adverse effects, the subcommittee has chosen amoxicillin as first-line AOM treatment. For head-to-head comparisons, stringent diagnostic criteria should be the standard for these studies, antibiotic comparisons for AOM should now include an observation arm for patients with nonsevere illness to ensure a clinical benefit over placebo, and studies should also have enough patients to show small but meaningful differences. Additional research is needed to determine whether risk factors such as child care settings and siblings younger than 5 years indicate a need for different initial treatment, to develop new antibiotics that are safe and effective and test them against the currently available medications, and to conduct randomized controlled trials using different durations of antibiotic therapy in different age groups to optimize therapy with the possibility of decreasing duration of antibiotic use, which would need to be performed initially with amoxicillin and amoxicillin-clavulanate and again include an observation arm in nonsevere illness.

---

### The diagnosis and management of acute otitis media [^113UpHvh]. Pediatrics (2013). Medium credibility.

Key action statement 4A — For acute otitis media (AOM), clinicians should prescribe amoxicillin for AOM when a decision to treat with antibiotics has been made and the child has not received amoxicillin in the past 30 days or the child does not have concurrent purulent conjunctivitis or the child is not allergic to penicillin (Evidence Quality: Grade B, Rec. Strength: Recommendation); benefits include that amoxicillin is effective for most children with AOM and is inexpensive, safe, has acceptable taste, and a narrow antimicrobial spectrum, while risks include ineffectiveness against β-lactamase–producing organisms and adverse effects of amoxicillin, with a preponderance of benefit noted; exclusions include patients with known penicillin allergy, and clinicians must determine whether the patient is truly penicillin allergic, with patient preferences considered if there was previous bad experience with amoxicillin.

---

### The diagnosis and management of acute otitis media [^112PEiiR]. Pediatrics (2013). Medium credibility.

Acute otitis media — first-line antibiotic therapy and dosing: High-dose amoxicillin is recommended as the first-line treatment in most patients, with amoxicillin 80–90 mg/kg per day in 2 divided doses as the recommended first-line regimen. In children who have taken amoxicillin in the previous 30 days, those with concurrent conjunctivitis, or those for whom coverage for β-lactamase–positive Haemophilus influenzae and Moraxella catarrhalis is desired, therapy should be initiated with high-dose amoxicillin-clavulanate, specified as 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate (amoxicillin to clavulanate ratio 14:1) given in 2 divided doses.

---

### Treatment and prevention of otitis media [^113tSKY3]. The Annals of Pharmacotherapy (2000). Low credibility.

Objective

To review and summarize recent advances in the treatment and prevention of otitis media (OM).

Data Sources

A MEDLINE search (1996-March 2000) was performed to identify relevant primary and review articles. References from these articles were also reviewed if deemed important.

Study Selection and Data Extraction

English-language primary and review articles focusing on the treatment and prevention of acute otitis media (AOM) were included. Studies focusing exclusively on OM with effusion or serous OM and chronic suppurative OM were excluded. Information regarding prevention and drug therapy was reviewed, with an emphasis placed on advances made in the last two years.

Data Synthesis

Recently, an expert panel of the Centers for Disease Control and Prevention recommended use of only three of 16 systemic antibiotics approved by the Food and Drug Administration for treatment of AOM: amoxicillin, cefuroxime axetil, and ceftriaxone. Controversy exists over the importance of key selection factors used by the expert panel in determining which antibiotics to recommend in a two-step treatment algorithm, that is, in vitro data, pharmacodynamic profiles, and necessity for coverage of drug-resistant Streptococcus pneumoniae at all steps of empiric treatment. Additional antibiotic and patient selection factors useful for individualizing therapy include clinical efficacy, adverse effects, frequency and duration of administration, taste, cost, comorbid infections, and ramifications should bacterial resistance develop to the chosen antibiotic. Presumed or past patient/caregiver adherence (especially when antibiotic failure has occurred) is also paramount in selecting antibiotic therapy. A three-step treatment algorithm for refractory AOM that employs amoxicillin, trimethoprim/sulfamethoxazole (TMP/SMX), or high-dose amoxicillin/clavulanate (depending on the prior dose of and adherence to amoxicillin therapy), and ceftriaxone or tympanocentesis at steps 1, 2, and 3, respectively, appears rational and cost-effective. The recent upsurge in antimicrobial resistance is highlighted, and recommendations are presented for the treatment of AOM and prevention of recurrent otitis media (rAOM).

Conclusions

Amoxicillin remains the antibiotic of choice for initial empiric treatment of AOM, although the traditional dosage should be increased in patients at risk for drug-resistant S. pneumoniae. In cases refractory to high-dose amoxicillin, TMP/SMX should be prescribed if adherence to prior therapy seemed good or complete, or high-dose amoxicillin/clavulanate if adherence was incomplete or questionable. Ceftriaxone should be reserved as third-line treatment. The increasing prevalence of drug-resistant S. pneumoniae emphasizes the importance of alternative medical approaches for the prevention of OM, as well as judicious antibiotic use in established cases. Removal of modifiable risk factors should be first-line therapy for prevention of rAOM. We support the use of conjugate pneumococcal vaccine per guidelines for prevention of rAOM from the Advisory Committee on Immunization Practice of the Centers for Disease Control and Prevention, with consideration given to influenza vaccine for cases of rAOM that historically worsen during the flu season. Sulfisoxazole prophylaxis should be reserved for children who are immunocompromised, have concurrent disease states exacerbated by AOM, or meet the criteria of rAOM despite conjugate pneumococcal and influenza vaccination. Therapy should be intermittent, beginning at the first sign of an upper respiratory infection, and should continue for 10 days. The invasive nature and risks of anesthesia relegate myringotomy, tympanostomy tubes, and adenoidectomy to last-line therapies for rAOM.

---

### Amoxicillin [^11641pg4]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (mild-to-moderate) is 25 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptom resolution

---

### Amoxicillin [^117F7x9h]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients ≤ 3 months) is up to 30 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptom resolution

---

### Diagnosis and treatment of acute otitis media: an assessment [^115xj3BT]. Pediatrics (2003). Low credibility.

Objective

To assess compliance with the Centers for Disease Control and Prevention (CDC) evidence-based guidelines for the judicious use of antimicrobials in children with acute otitis media (AOM).

Methods

Compliance with CDC's recommended diagnostic criteria and antimicrobial treatments for management of AOM was assessed by chart review and self-report for 29 community pediatricians in St. Louis, Missouri. For each physician, a simple random sample of AOM visits was selected and reviewed by trained reviewers. In addition, each physician completed a questionnaire.

Results

Compliance with recommended diagnostic criteria was 38% (95% confidence interval: 34%-42%; n = 573) by chart audit and 41% (95% confidence interval: 24%-61%; n = 29) by self-report. Antimicrobial selection assessed by chart audit was consistent with CDC guidelines in 68% (95% confidence interval: 64%-72%) of visits for a new infection, 63% (95% confidence interval: 47%-78%) of visits for treatment failure, and 50% (95% confidence interval: 33%-67%) for recurrent disease. Self-reported compliance with treatment guidelines for new infection was 100% (95% confidence interval: 88%-100%) and 83% (95% confidence interval: 64%-94%) for treatment failure. Noncompliance was most frequently attributable to overuse of broad-spectrum antimicrobials. Most patients treated with amoxicillin received a 10-day course (98%). Subtherapeutic dosing occurred in 26% of patients treated with amoxicillin.

Conclusions

Overdiagnosis of AOM is common. Efforts to improve the judicious use of antimicrobials for AOM should focus on improving diagnostic accuracy, limiting the use of broad-spectrum antimicrobials to cases where they offer clinical benefit, and ensuring that amoxicillin dosing regimens are optimal.

---

### Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children [^113JuKfH]. The Pediatric Infectious Disease Journal (2003). Low credibility.

Background

High dose (70 to 90 mg/kg/day) amoxicillin is recommended as first line therapy of acute otitis media (AOM) in geographic areas where drug-resistant Streptococcus pneumoniae is prevalent. Information on the bacteriologic efficacy of high dose amoxicillin treatment for AOM is limited.

Objectives

To evaluate the bacteriologic and clinical efficacy of high dose amoxicillin as first line therapy in AOM.

Methods

In a prospective study 50 culture-positive patients ages 3 to 22 months (median, 9 months; 77% < 1 year) were treated with high dose amoxicillin (80 mg/kg/day three times a day for 10 days) No antibiotics were administered 72 h before enrollment. Twenty-four (48%) patients presented with their first episode of AOM. Middle ear fluid was cultured by tympanocentesis at enrollment and on Days 4 to 6 of therapy. Additional middle ear fluid cultures were obtained if clinical relapse occurred. Bacteriologic failure was defined by positive cultures on Days 4 to 6 and clinical failure by no change or worsening of AOM signs and symptoms and requirement for additional antibiotics during therapy and/or at end of therapy. Patients were followed until Day 28 ± 2. Susceptibility to penicillin and amoxicillin was measured by E-test.

Results

Sixty-five organisms were recovered at enrollment: Haemophilus influenzae (38), Streptococcus pneumoniae (24), Streptococcus pyogenes (2) and Moraxella catarrhalis (1). Eighteen (75%) S. pneumoniae were nonsusceptible to penicillin (MIC > 0.1 microg/ml). All 24 S. pneumoniae isolates had amoxicillin MIC ≤ 2.0 microg/ml. Thirteen (34%) of the 38 H. influenzae were beta-lactamase producers. Eradication was achieved in 41 (82%) patients for 54 of 65 (83%) pathogens: 22 of 24 (92%) S. pneumoniae, 21 of 25 (84%) beta-lactamase-negative H. influenzae, 8 of 13 (62%) beta-lactamase-positive H. influenzae, 2 of 2 S. pyogenes and 1 of 1 M. catarrhalis. Seven organisms not initially present were isolated on Days 4 to 6 in 5 patients: 3 beta-lactamase-positive H. influenzae; 1 beta-lactamase-negative H. influenzae; 2 S. pneumoniae; and 1 M. catarrhalis. In total 14 of 50 (28%) patients failed bacteriologically on Days 4 to 6 (persistence + new infection), of whom 9 (64%) had beta-lactamase-positive H. influenzae. Three (33%) of the 9 patients with bacteriologic failure (2 beta-lactamase-positive H. influenzae, 1 S. pneumoniae) failed also clinically on Days 4 to 6.

Conclusions

The predominant pathogens isolated from children with AOM failing high dose amoxicillin therapy were beta-lactamase-producing organisms. Because its overall clinical efficacy is good, high dose amoxicillin is still an appropriate choice as first line empiric therapy for AOM, followed by a beta-lactamase-stable drug in the event of failure.

---

### Cefprozil versus high-dose amoxicillin / clavulanate in children with acute otitis media [^116gYckn]. Clinical Therapeutics (2001). Low credibility.

Background

The recommendation of the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group that high-dose amoxicillin, with or without clavulanate, be used to treat acute otitis media (AOM) addressed concerns about the efficacy of existing therapies against drug-resistant S. pneumoniae. This recommendation relied on pharmacodynamic predictions of concentrations of amoxicillin in middle-ear fluid remaining higher than minimum inhibitory concentrations against intermediately resistant S. pneumoniae for > 40% of the dosing interval.

Objective

This study compared the tolerability and efficacy of cefprozil and high-dose amoxicillin/clavulanate in patients with AOM.

Methods

Patients were randomized to receive 10 days of investigator-blinded oral treatment with either cefprozil suspension (30 mg/kg/d in 2 divided doses) or amoxicillin/clavulanate (45/6.4 mg/kg/d) plus amoxicillin (45 mg/kg/d) in 2 divided doses. The primary efficacy end point was the clinical cure rate 4 to 7 days after the end of treatment. Clinical response by age (6 months- < 2 years vs ≥ 2–7 years), disease severity, and unilateral versus bilateral ear infection was also examined. The primary measures of tolerability were the frequency and severity of adverse events and their relation to study drug. Adverse events were either spontaneously reported or elicited during examination and questioning of the patient. Identified adverse events were coded and recorded using the COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms) system.

Results

Three hundred four children between the ages of 6 months and 7 years with ≥ 1 sign or symptom of AOM were enrolled in the study, and 303 (150 cefprozil, 153 amoxicillin/clavulanate) were treated. Twenty-three patients in each treatment group were not evaluable; thus, 257 children were included in the analysis of evaluable patients. Clinical cure rates were 87% (110/127) with cefprozil and 89% (116/130) with amoxicillin/clavulanate (95% CI for the difference in cure rate, -10.7% to 4.1%). No between-group differences in efficacy were noted by age, disease severity, or unilateral or bilateral involvement. The overall incidence of drug-related adverse events was significantly lower with cefprozil than with amoxicillin/clavulanate (19% vs 32%, respectively; P = 0.008), as was the incidence of diarrhea (9% vs 19%, respectively; P = 0.021). Adverse events prompted discontinuation of therapy in 4 (3%) cefprozil patients and 8 (5%) amoxicillin/clavulanate patients.

Conclusions

Based on a search of MEDLINE, this study is the first direct comparison of cefprozil versus high-dose amoxicillin/clavulanate. Cefprozil was as effective as high-dose amoxicillin/clavulanate, with a lower incidence of adverse events.

---

### Outpatient antibiotic prescribing for 357, 390 children with otitis media [^117RDWL8]. The Pediatric Infectious Disease Journal (2022). Medium credibility.

Otitis media (OM) is a common complication of respiratory tract infections in children. Over 130,000 acute OM cases were diagnosed and treated in Finnish children in public health care centers in 2014. Nearly half of the infants have suffered from acute OM during their first living year and 70% before the age of 2 years. Among 17 European evidence-based guidelines, all recommend analgesics, and 15 recommend the wait-and-see practice in selected cases, and when treated, 14 recommend amoxicillin as the first-choice antibiotics: 7 with the dose of 40–50 mg/kg/day and 7 with the dose of 90 mg/kg/day.

The Finnish Current Care Guidelines for diagnosis and treatment of OM, which were published in 2011 and updated in 2017, are in line with the European guidelines. The Finnish guidelines recommend that children younger than 24 months of age, and children with bulging eardrum, draining middle ear or purulent OM in both ears should be treated immediately, and the first-line antibiotics are amoxicillin or amoxicillin-clavulanic acid. High amoxicillin dosing is not needed due to the low frequency of pneumococcal penicillin resistance in the country. Second-generation cephalosporins, trimethoprim-sulfa and macrolides are the second-line drugs recommended for those allergic to penicillin. Children 2 years of age and upward with less prominent clinical findings can be left without antibiotics, but they must be reexamined after 2 to 3 days if the symptoms continue.

A task force set up by the European Paediatric Association concluded that the overconsumption of antibiotics in children with spontaneously recovering respiratory tract infections is 1 of the 4 most important health care problems in children in Europe. Indeed, many children with signs and symptoms of OM during acute respiratory infection recover spontaneously, and a wait-and-see practice with delayed introduction of antibiotics, if needed, is justified in appropriate cases and eventually reduces the consumption of antibiotics at the population level.

The aim of the present study was to evaluate antibiotic prescriptions for children with OM in a nationwide private network of outpatient clinics in Finland. Special focus was paid to amoxicillin and amoxicillin-clavulanic acid prescriptions, which have been the first-choice recommendations since 2017, according to Finnish guidelines. A nationwide dataset allowed an estimation of variations by age, time, region and the specialty of the physicians. Further, we were interested in identifying potential needs and specific areas for future active interventions antibiotic use among children with OM.

---

### The diagnosis and management of acute otitis media [^1138jF4i]. Pediatrics (2013). Medium credibility.

Acute otitis media (AOM) — bacterial susceptibility to antibiotics and dosing: Early studies show that 19% of children with S pneumoniae and 48% with H influenzae cultured on initial tympanocentesis who were not treated with antibiotic cleared the bacteria at the time of a second tympanocentesis 2 to 7 days later, and approximately 75% of children infected with M catarrhalis experienced bacteriologic cure even after treatment with amoxicillin, an antibiotic to which it is not susceptible. Current US data indicate that approximately 83% and 87% of isolates of S pneumoniae from all age groups are susceptible to regular (40 mg/kg/day) and high-dose amoxicillin (80–90 mg/kg/day divided twice daily), respectively. High-dose amoxicillin will yield middle ear fluid levels that exceed the minimum inhibitory concentration (MIC) of all S pneumoniae serotypes that are intermediately resistant to penicillin (penicillin MICs, 0.12–1.0 μg/mL), and may not hit all highly resistant serotypes (penicillin MICs, ≥ 2 μg/mL) for a longer period of the dosing interval and has been shown to improve bacteriologic and clinical efficacy.

---

### Amoxicillin (Amoxil) [^111BBiQ9]. FDA (2023). Medium credibility.

DOSAGE AND ADMINSTRATION

2.1 Dosing for Adult and Pediatric Patients > 3 Months of Age

Except for gonorrhea, treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. It is recommended that there be at least 10 days' treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever. In some infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.

Table 1. Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity a Usual Adult Dose Usual Dose for Children > 3 Monthsb

Ear/Nose/Throat

Skin/ Skin Structure

Genitourinary Tract Mild/

Moderate 500 mg every 12 hours or 250 mg every 8 hours 25 mg/kg/day in divided doses every 12 hours

or

20 mg/kg/day in divided doses every 8 hours

Severe 875 mg every 12 hours or 500 mg every 8 hours 45 mg/kg/day in divided doses every 12 hours

or

40 mg/kg/day in divided doses every 8 hours

Lower Respiratory Tract

Mild/

Moderate or Severe 875 mg every 12 hours or 500 mg every 8 hours 45 mg/kg/day in divided doses every 12 hours

---

### Amoxicillin [^116xCqCn]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (mild-to-moderate) is 20 mg/kg PO daily, in 3 divided doses, until 48–72 hours of symptom resolution

---

### Amoxicillin [^113fsRXd]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (severe) is 40 mg/kg PO daily, in 3 divided doses, until 48–72 hours of symptom resolution

---

### Amoxicillin [^116ouRb4]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (severe) is 45 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptom resolution

---

### Amoxicillin [^115gcob5]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (mild-to-moderate) is 250 mg PO TID until 48–72 hours of symptom resolution

---

### Amoxicillin [^112fbXgD]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (mild-to-moderate) is 500 mg PO BID until 48–72 hours of symptom resolution

---

### Otitis media: review of the 2004 treatment guidelines [^114T49UA]. The Annals of Pharmacotherapy (2005). Low credibility.

Objective

To review the 2004 treatment guidelines provided by the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) regarding the treatment of otitis media in pediatric patients.

Data Sources

A MEDLINE search, restricted to English-language articles about pediatric patients, was conducted (1966-May 2005) using the key words acute otitis media (AOM), guideline, observation therapy, and vaccination. Additional references were located through review of the bibliographies of cited articles.

Study Selection and Data Extraction

Studies related to the fundamental basis of the updated guidelines and articles addressing current issues related to otitis media infection were included.

Data Synthesis

Otitis media affects many children in the US. Concerns have been raised about the proper treatment of AOM in the face of increasing drug resistance among primary pathogens responsible for infection. Some countries have chosen to observe patients for a designated period of time prior to initiation of antibiotic therapy. The AAP and AAFP have updated the treatment guidelines for otitis media to include the option of observation therapy, recommendations for dosing of various antibiotic regimens and their place in therapy, and the importance of initial pain management.

Conclusions

Updated treatment guidelines for otitis media have been developed in an effort to properly treat children while decreasing current resistance rates for common organisms that cause AOM. In the future, the therapeutic outcomes of observation therapy related to both the incidence of drug resistance and the possibility of increased complications related to otitis media will need to be evaluated in the US.

---

### Large dosage amoxicillin / clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children [^116avFi8]. The Pediatric Infectious Disease Journal (2005). Low credibility.

Background

A large dosage pediatric formulation of amoxicillin/clavulanate with an improved pharmacokinetic/pharmacodynamic profile was developed to eradicate many penicillin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae (including beta-lactamase-producing strains).

Methods

This randomized, investigator-blinded, multicenter trial examined treatment of bacterial acute otitis media (AOM) in children 6–30 months of age with amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses for 10 days) versus azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days). Tympanocentesis was performed at entry for bacteriologic assessment, at the on-therapy visit (day 4–6) to determine bacterial eradication and at any time before the end-of-therapy visit (day 12–14) if the child was categorized as experiencing clinical failure. Clinical assessments were performed at the on-therapy, end-of-therapy and follow-up (day 21–25) visits.

Results

We enrolled 730 children; AOM pathogens were isolated at baseline for 249 of the amoxicillin/clavulanate group and 245 of the azithromycin group. For children with AOM pathogens at baseline, clinical success rates at the end-of-therapy visit were 90.5% for amoxicillin/clavulanate versus 80.9% for azithromycin (P < 0.01), and those at the on-therapy and follow-up visits were 94.9% versus 88.0% and 80.3% versus 71.1%, respectively (all P < 0.05). At the on-therapy visit, pretherapy pathogens were eradicated for 94.2% of children receiving amoxicillin/clavulanate versus 70.3% of those receiving azithromycin (P < 0.001). Amoxicillin/clavulanate eradicated 96.0% of S. pneumoniae (92.0% of fully penicillin-resistant S. pneumoniae) and 89.7% of H. influenzae (85.7% [6 of 7 cases] of beta-lactamase-positive H. influenzae). Corresponding rates for azithromycin were 80.4% (54.5%) for S. pneumoniae and 49.1% (100% [1 of 1 case]) for H. influenzae (all P < 0.01 for between-drug comparisons).

Conclusion

Amoxicillin/clavulanate was clinically and bacteriologically more effective than azithromycin among children with bacterial AOM, including cases caused by penicillin-resistant S. pneumoniae and beta-lactamase-positive H. influenzae.

---

### The diagnosis and management of acute otitis media [^114HRxCA]. Pediatrics (2013). Medium credibility.

Acute otitis media — management after 48–72 hours of failure of initial antibiotic treatment: For antibiotic treatment after 48–72 h of failure of initial antibiotic treatment, recommended first-line options include amoxicillin–clavulanate (90 mg/kg per day of amoxicillin, with 6.4 mg/kg per day of clavulanate [amoxicillin to clavulanate ratio, 14:1] in 2 divided doses) and ceftriaxone (50 mg IM or IV per day for 1 or 3 d); alternative treatment includes clindamycin (30–40 mg/kg per day in 3 divided doses) with or without a third-generation cephalosporin, and tympanocentesis with specialist consultation per footnote guidance.

---

### The diagnosis and management of acute otitis media [^115vFj9E]. Pediatrics (2013). Medium credibility.

Acute otitis media (AOM) guideline — this evidence-based clinical practice guideline provides recommendations to primary care clinicians for the management of children from 6 months through 12 years of age with uncomplicated AOM and focuses on appropriate diagnosis and initial treatment. The guideline provides a specific, stringent definition of AOM and addresses pain management, initial observation versus antibiotic treatment, appropriate choices of antibiotic agents, and preventive measures, and it also addresses recurrent AOM. Decisions were made on the basis of a systematic grading of the quality of evidence and benefit-harm relationships, and the practice guideline underwent comprehensive peer review before formal approval by the American Academy of Pediatrics. The guideline is not intended as a sole source of guidance; rather, it is intended to assist primary care clinicians by providing a framework for clinical decision-making, not to replace clinical judgment or establish a protocol for all children, and these recommendations may not provide the only appropriate approach to management.

---

### The diagnosis and management of acute otitis media [^115Sosyg]. Pediatrics (2013). Medium credibility.

Key action statement 4B — When additional β-lactamase coverage is needed in acute otitis media (AOM), clinicians should prescribe an antibiotic with additional β-lactamase coverage for AOM when a decision to treat with antibiotics has been made and the child has received amoxicillin in the past 30 days or has concurrent purulent conjunctivitis or has a history of recurrent AOM unresponsive to amoxicillin (Evidence Quality: Grade C, Rec. Strength: Recommendation); benefits include successful treatment of β-lactamase–producing organisms, with risks of cost and increased adverse effects, a preponderance of benefit, the value judgment that efficacy is more important than taste, exclusions of patients with known penicillin allergy, and consideration of patient concerns regarding side effects and taste.

---

### Amoxicillin [^113TG7XQ]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (severe) is 500 mg PO TID until 48–72 hours of symptom resolution

---

### Amoxicillin [^113oAhT6]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in both children (in patients > 3 months) (severe) is 875 mg PO BID until 48–72 hours of symptom resolution

---

### Amoxicillin [^112V5fxT]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in adults (mild-to-moderate) is 250 mg PO TID until 48–72 hours of symptom resolution

---

### Amoxicillin [^117GgPV8]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in adults (mild-to-moderate) is 500 mg PO BID until 48–72 hours of symptom resolution

---

### Antibiotics for acute otitis media in children [^1167djHn]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Acute otitis media (AOM) is one of the most common diseases in childhood for which antibiotics are commonly prescribed; a systematic review reported a pooled prevalence of 85.6% in high-income countries. This is an update of a Cochrane Review first published in the Cochrane Library in 1997 and updated in 1999, 2005, 2009, 2013 and 2015.

Objectives

To assess the effects of antibiotics for children with AOM.

Search Methods

We searched CENTRAL, MEDLINE, Embase, Current Contents, CINAHL, LILACS and two trial registers. The date of the search was 14 February 2023.

Selection Criteria

We included randomised controlled trials comparing 1) antimicrobial drugs with placebo, and 2) immediate antibiotic treatment with expectant observation (including delayed antibiotic prescribing) in children with AOM.

Data Collection and Analysis

Two review authors independently screened trials for inclusion and extracted data using the standard methodological procedures recommended by Cochrane. Our primary outcomes were: 1) pain at various time points (24 hours, two to three days, four to seven days, 10 to 14 days), and 2) adverse effects likely to be related to the use of antibiotics. Secondary outcomes were: 1) abnormal tympanometry findings, 2) tympanic membrane perforation, 3) contralateral otitis (in unilateral cases), 4) AOM recurrences, 5) serious complications related to AOM and 6) long-term effects (including the number of parent-reported AOM symptom episodes, antibiotic prescriptions and health care utilisation as assessed at least one year after randomisation). We used the GRADE approach to rate the overall certainty of evidence for each outcome of interest.

Main Results

Antibiotics versus placebo We included 13 trials (3401 children and 3938 AOM episodes) from high-income countries, which we assessed at generally low risk of bias. Antibiotics do not reduce pain at 24 hours (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.78 to 1.01; 5 trials, 1394 children; high-certainty evidence), or at four to seven days (RR 0.76, 95% CI 0.50 to 1.14; 7 trials, 1264 children), but result in almost a third fewer children having pain at two to three days (RR 0.71, 95% CI 0.58 to 0.88; number needed to treat for an additional beneficial outcome (NNTB) 20; 7 trials, 2320 children; high-certainty evidence), and likely result in two-thirds fewer having pain at 10 to 12 days (RR 0.33, 95% CI 0.17 to 0.66; NNTB 7; 1 trial, 278 children; moderate-certainty evidence). Antibiotics increase the risk of adverse events such as vomiting, diarrhoea or rash (RR 1.38, 95% CI 1.16 to 1.63; number needed to treat for an additional harmful outcome (NNTH) 14; 8 trials, 2107 children; high-certainty evidence). Antibiotics reduce the risk of children having abnormal tympanometry findings at two to four weeks (RR 0.83, 95% CI 0.72 to 0.96; NNTB 11; 7 trials, 2138 children), slightly reduce the risk of experiencing tympanic membrane perforations (RR 0.43, 95% CI 0.21 to 0.89; NNTB 33; 5 trials, 1075 children) and halve the risk of contralateral otitis episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11; 4 trials, 906 children). However, antibiotics do not reduce the risk of abnormal tympanometry findings at six to eight weeks (RR 0.89, 95% CI 0.70 to 1.13; 3 trials, 953 children) and at three months (RR 0.94, 95% CI 0.66 to 1.34; 3 trials, 809 children) or late AOM recurrences (RR 0.94, 95% CI 0.79 to 1.11; 6 trials, 2200 children). Severe complications were rare, and the evidence suggests that serious complications do not differ between children treated with either antibiotics or placebo. Immediate antibiotics versus expectant observation We included six trials (1556 children) from high-income countries. The evidence suggests that immediate antibiotics may result in a reduction of pain at two to three days (RR 0.53, 95% CI 0.35 to 0.79; NNTB 8; 1 trial, 396 children; low-certainty evidence), but probably do not reduce the risk of pain at three to seven days (RR 0.75, 95% CI 0.50 to 1.12; 4 trials, 959 children; moderate-certainty evidence), and may not reduce the risk of pain at 11 to 14 days (RR 0.91, 95% CI 0.75 to 1.10; 1 trial, 247 children; low-certainty evidence). Immediate antibiotics increase the risk of vomiting, diarrhoea or rash (RR 1.87, 95% CI 1.39 to 2.51; NNTH 10; 3 trials, 946 children; high-certainty evidence). Immediate antibiotics probably do not reduce the proportion of children with abnormal tympanometry findings at four weeks and evidence suggests that immediate antibiotics may not reduce the risk of tympanic membrane perforation and AOM recurrences. No serious complications occurred in either group.

Authors' Conclusions

This review reveals that antibiotics probably have no effect on pain at 24 hours, a slight effect on pain in the days following and only a modest effect on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to four weeks compared with placebo in children with AOM. In high-income countries, most cases of AOM spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children treated with antibiotics, one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if antibiotics were withheld. For most children with mild disease in high-income countries, an expectant observational approach seems justified. Therefore, clinical management should emphasise advice about adequate analgesia and the limited role for antibiotics.

---

### The diagnosis and management of acute otitis media [^114dCz5f]. Pediatrics (2013). Medium credibility.

American Academy of Pediatrics — Key Action Statement 5A for recurrent acute otitis media (AOM): Clinicians should NOT prescribe prophylactic antibiotics to reduce the frequency of episodes of AOM in children with recurrent AOM, with Evidence Quality: Grade B and Recommendation Strength: Recommendation.

---

### The diagnosis and management of acute otitis media [^1173F3P5]. Pediatrics (2013). Medium credibility.

Purpose of this section — if an antibiotic will be used for treatment of a child with AOM, the clinician must choose an antibiotic with a high likelihood of being effective against the most likely etiologic bacterial pathogens with considerations of cost, taste, convenience, and adverse effects, and this section proposes first- and second-line antibiotics that best meet these criteria while balancing potential benefits and harms.

---

### The diagnosis and management of acute otitis media [^114QS4kC]. Pediatrics (2013). Medium credibility.

Acute otitis media (AOM) randomized trial protocol in toddlers — amoxicillin-clavulanate versus placebo — specified dose, population, definition, compliance, and outcome. Tähtinen et al conducted a randomized, double-blind, placebo-controlled, intention-to-treat study of amoxicillin-clavulanate (40 mg/kg/day) versus placebo. Three hundred nineteen patients from 6 to 35 months of age were studied: 161 in the antibiotic group and 158 in the placebo group. AOM definition was the presence of MEE, distinct erythema over a bulging or yellow TM, and acute symptoms such as ear pain, fever, or respiratory symptoms. Compliance was measured by using daily patient diaries and number of capsules remaining at the end of the study. Primary outcome was time to treatment failure defined as a composite of 6 independent components.

---

### The diagnosis and management of acute otitis media [^112o3Edr]. Pediatrics (2013). Medium credibility.

Acute otitis media — antibiotic selection and reassessment: Clinicians should prescribe amoxicillin for AOM when a decision to treat with antibiotics has been made and the child has not received amoxicillin in the past 30 days or the child does not have concurrent purulent conjunctivitis, or the child is not allergic to penicillin; clinicians should prescribe an antibiotic with additional β-lactamase coverage for AOM when a decision to treat with antibiotics has been made, and the child has received amoxicillin in the last 30 days or has concurrent purulent conjunctivitis, or has a history of recurrent AOM unresponsive to amoxicillin; clinicians should reassess the patient if the caregiver reports that the child's symptoms have worsened or failed to respond to the initial antibiotic treatment within 48 to 72 hours and determine whether a change in therapy is needed.

---

### Otitis media: diagnosis and treatment [^114DqTAM]. American Family Physician (2013). Low credibility.

Acute otitis media is diagnosed in patients with acute onset, presence of middle ear effusion, physical evidence of middle ear inflammation, and symptoms such as pain, irritability, or fever. Acute otitis media is usually a complication of eustachian tube dysfunction that occurs during a viral upper respiratory tract infection. Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are the most common organisms isolated from middle ear fluid. Management of acute otitis media should begin with adequate analgesia. Antibiotic therapy can be deferred in children two years or older with mild symptoms. High-dose amoxicillin (80 to 90 mg per kg per day) is the antibiotic of choice for treating acute otitis media in patients who are not allergic to penicillin. Children with persistent symptoms despite 48 to 72 hours of antibiotic therapy should be reexamined, and a second-line agent, such as amoxicillin/clavulanate, should be used if appropriate. Otitis media with effusion is defined as middle ear effusion in the absence of acute symptoms. Antibiotics, decongestants, or nasal steroids do not hasten the clearance of middle ear fluid and are not recommended. Children with evidence of anatomic damage, hearing loss, or language delay should be referred to an otolaryngologist.

---

### Amoxicillin [^115zPLen]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in adults (severe) is 500 mg PO TID until 48–72 hours of symptom resolution

---

### The diagnosis and management of acute otitis media [^1162orWZ]. Pediatrics (2013). Medium credibility.

Regarding medical management for acute otitis media, more specifically with respect to systemic antibiotics, indications, young children, AAFP/AAP 2013 guidelines recommend to consider initiating antibiotic therapy or offering observation with close follow-up in patients aged 6–23 months without severe signs or symptoms. Initiate antibiotic therapy if the child worsens or fails to improve within 48–72 hours of the onset of symptoms.

---

### Treatment of acute otitis media in children under 2 years of age [^115djLqd]. The New England Journal of Medicine (2011). Excellent credibility.

Background

Recommendations vary regarding immediate antimicrobial treatment versus watchful waiting for children younger than 2 years of age with acute otitis media.

Methods

We randomly assigned 291 children 6 to 23 months of age, with acute otitis media diagnosed with the use of stringent criteria, to receive amoxicillin-clavulanate or placebo for 10 days. We measured symptomatic response and rates of clinical failure.

Results

Among the children who received amoxicillin-clavulanate, 35% had initial resolution of symptoms by day 2, 61% by day 4, and 80% by day 7; among children who received placebo, 28% had initial resolution of symptoms by day 2, 54% by day 4, and 74% by day 7 (P = 0.14 for the overall comparison). For sustained resolution of symptoms, the corresponding values were 20%, 41%, and 67% with amoxicillin-clavulanate, as compared with 14%, 36%, and 53% with placebo (P = 0.04 for the overall comparison). Mean symptom scores over the first 7 days were lower for the children treated with amoxicillin-clavulanate than for those who received placebo (P = 0.02). The rate of clinical failure — defined as the persistence of signs of acute infection on otoscopic examination — was also lower among the children treated with amoxicillin-clavulanate than among those who received placebo: 4% versus 23% at or before the visit on day 4 or 5 (P < 0.001) and 16% versus 51% at or before the visit on day 10 to 12 (P < 0.001). Mastoiditis developed in one child who received placebo. Diarrhea and diaper-area dermatitis were more common among children who received amoxicillin-clavulanate. There were no significant changes in either group in the rates of nasopharyngeal colonization with nonsusceptible Streptococcus pneumoniae.

Conclusions

Among children 6 to 23 months of age with acute otitis media, treatment with amoxicillin-clavulanate for 10 days tended to reduce the time to resolution of symptoms and reduced the overall symptom burden and the rate of persistent signs of acute infection on otoscopic examination. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00377260.).

---

### Outpatient antibiotic prescribing for 357, 390 children with otitis media [^113XAvco]. The Pediatric Infectious Disease Journal (2022). Medium credibility.

CONCLUSION

We found evidence that adherence to the Finnish Current Care guidelines on the treatment of OM in children was rather good. Less than half received antibiotics, and the great majority received amoxicillin or amoxicillin-clavulanic acid, which were the first-choice recommendations in the guidelines. To further increase concordance, active interventions should especially be targeted to tackle the identified challenges (eg, specialty or age group). Existing EHR systems could be armed with automated guideline-specific algorithms tailored according to diagnosis, patient group and physician's specialty. Combining such systems with real-time monitoring and systematic feedback for physicians could facilitate the adaptation of various guidelines to day-to-day practice.

---

### The diagnosis and management of acute otitis media [^1135fz6j]. Pediatrics (2013). Medium credibility.

Acute otitis media (AOM) duration of therapy by age and severity: The optimal duration is uncertain, but for children younger than 2 years and children with severe symptoms, a standard 10-day course is recommended. A 7-day course appears equally effective in children 2 to 5 years of age with mild or moderate AOM, and for children 6 years and older with mild to moderate symptoms, a 5- to 7-day course is adequate treatment.

---

### Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants [^115UEwBR]. BMJ (2009). Excellent credibility.

Objective To determine the long term effects of antibiotic treatment for acute otitis media in young children.

Design Prospective three year follow-up study within the framework of a primary care based, double blind, randomised, placebo controlled trial.

Setting 53 general practices in the Netherlands.

Participants 168 children aged 6 months to 2 years with acute otitis media.

Interventions Amoxicillin 40 mg/kg/day in three doses compared with placebo.

Main outcome measures Recurrence of acute otitis media; referral to secondary care; ear, nose, and throat surgery.

Results Acute otitis media recurred in 63% (47/75) of children in the amoxicillin group and in 43% (37/86) of the placebo group (risk difference 20%, 95% confidence interval 5% to 35%); 30% (24/78 amoxicillin; 27/89 placebo) of children in both groups were referred to secondary care, and 21% (16/78) of the amoxicillin group compared with 30% (27/90) of the placebo group had ear, nose, and throat surgery (risk difference −9%, −23% to 4%).

Conclusion Recurrent acute otitis media occurred more often in the children originally treated with amoxicillin. This is another argument for judicious use of antibiotics in children with acute otitis media.

Trial registration Netherlands Trial Register NTR1426.

---

### Amoxicillin [^113A9ZvN]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute otitis media in adults (severe) is 875 mg PO BID until 48–72 hours of symptom resolution

---

### The diagnosis and management of acute otitis media [^115Draen]. Pediatrics (2013). Medium credibility.

Regarding medical management for acute otitis media, more specifically with respect to systemic antibiotics, indications, young children, AAFP/AAP 2013 guidelines recommend to initiate antibiotic therapy in patients aged 6–23 months with bilateral AOM, regardless of symptom severity.

---

### Preferred antibiotics for treatment of acute otitis media: comparison of practicing pediatricians, general practitioners, and otolaryngologists [^1149NNqU]. Clinical Pediatrics (2005). Low credibility.

The antibiotic preferences of 2,190 pediatricians (peds) 360 general practitioners (GPs), and 273 otolaryngologists (ENTs) in the United States and concurrence with treatment guideline recommendations for acute otitis media (AOM) for suspected drug-resistant Streptococcus pneumoniae (DRSP) and beta-lactamase-producing Haemophilus influenzae before and after an educational workshop were compared. Peds and GPs preferred amoxicillin/clavulanate high-dose, whereas ENTs preferred higher generation cephalosporins. Before the workshop, endorsement of guideline-recommended antibiotics for treatment of AOM caused by DRSP by Peds, GPs, and ENTs was 80%, 75%, and 78%, respectively, and for Haemophilus influenzae was 73%, 63%, and 84%, respectively. After the workshop concurrence with AOM guideline recommendations for DRSP increased to 96%, 95%, and 97% and for H. influenzae increased to 93%, 94%, and 96% for Peds, GPs, and ENTs, respectively (p < 0.0001 for all comparisons). Peds, GPs, and ENTs select appropriate antibiotics for AOM 63–84% of the time. After instruction that provides the rationale for guideline-recommended agents based on pharmacokinetics/pharmacodynamics and double tympanocentesis trials, endorsement of recommended antibiotics significantly improved to > 90%.

---

### Azithromycin [^117DGZeP]. FDA (2025). Medium credibility.

2 DOSAGE AND ADMINISTRATION

Adult Patients (2.1)

Pediatric Patients (2.2)

2.1 Adult Patients

[see Indications and Usage (1.1) and Clinical Pharmacology (12.3)]

Azithromycin tablets can be taken with or without food.

2.2 Pediatric Patients1

Azithromycin for oral suspension can be taken with or without food.

PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA, ACUTE BACTERIAL SINUSITIS, AND COMMUNITY-ACQUIRED PNEUMONIA (Age 6 months and above, [see Use in Specific Populations (8.4)]) Based on Body Weight

* Effectiveness of the 3-day or 1-day regimen in pediatric patients with community-acquired pneumonia has not been established.

*Effectiveness of the 5-day or 1-day regimen in pediatric patients with acute bacterial sinusitis has not been established.

The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.

Pharyngitis/Tonsillitis: The recommended dose of azithromycin for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)

PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS (Age 2 years and above, [see Use in Specific Populations (8.4)]) Based on Body Weight

---

### Amoxicillin and clavulanate potassium [^111QF4Le]. FDA (2025). Medium credibility.

14.2 Acute Bacterial Otitis Media and Diarrhea in Pediatric Patients

One U.S./Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of amoxicillin and clavulanate potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of amoxicillin and clavulanate potassium for 10 days in the treatment of acute otitis media. Only the suspension formulations were used in this trial. A total of 575 pediatric patients (aged 2 months to 12 years) were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., greater than or equal to 84%) per treatment group. Otitis media-specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow-up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow-up visit (defined as 22 to 28 days post-completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87% (n equals 265) and 82% (n equals 260) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. At follow-up, 67% (n equals 249) and 69% (n equals 243) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively.

---

### Pediatric acute otitis media: the case for delayed antibiotic treatment [^113CsUn7]. The Journal of Emergency Medicine (2007). Low credibility.

Acute otitis media (AOM) is both a commonly diagnosed condition and a frequent indication for antibiotic use in children. Recent literature suggests that antibiotics are not needed in many children with AOM, as most cases resolve spontaneously without complication. However, a majority of AOM infections in children are still treated with antibiotics. The American Academy of Pediatrics and American Academy of Family Physicians released a guideline for treatment of AOM in children. We review the guideline as well as scientific evidence related to AOM treatment options. We support a set of evidence-based guidelines employing a delayed prescription option for antibiotic therapy in selected children. If used appropriately, these cost-effective guidelines will reduce the amount of antibiotics prescribed, increase parental satisfaction, and may lower rates of antibiotic resistance while producing similar rates of resolution of AOM.

---

### Bacteriologic and clinical efficacy of high dose amoxicillin / clavulanate in children with acute otitis media [^11385buK]. The Pediatric Infectious Disease Journal (2001). Low credibility.

Objectives

To determine the bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate (90/6.4 mg/kg/day) against common bacterial pathogens causing acute otitis media (AOM), including penicillin-resistant Streptococcus pneumoniae (PRSP).

Methods

In this open label multicenter study, 521 infants and children with AOM [mean age, 18.6 months; age < 24 months, n = 375 (72%)] were treated with amoxicillin/clavulanate 90/6.4 mg/kg/day in two divided doses for 10 days. Bilateral otitis media, previous episodes of AOM, antibiotic treatment within 3 months and day-care attendance were recorded in 60.1, 35.7, 50.2 and 38.2% of the children, respectively. Tympanocentesis was performed before the first dose and repeated on Days 4 to 6 for all children with S. pneumoniae at 22 centers and for all children with any pathogen at 3 centers. Clinical response was assessed at end of therapy.

Results

Pathogens were isolated from 355 (68%) of 521 enrolled children; 180 children underwent repeat tympanocentesis and were bacteriologically evaluable. Baseline pathogens were S. pneumoniae (n = 122 enrolled/93 bacteriologically evaluable), Haemophilus influenzae (n = 160/51), both (n = 37/32) and others (n = 36/4). Pathogens were eradicated from 172 (96%) of 180 bacteriologically evaluable children. Overall 122 (98%) of 125 isolates of S. pneumoniae were eradicated, including 31 (91%) of 34 PRSP isolates (penicillin MICs 2 to 4 micrograms/ml). Seventy-eight (94%) of 83 isolates of H. influenzae were eradicated. Symptoms and otoscopic signs of acute inflammation were completely resolved or improved on Days 12 to 15 in 263 (89%) of 295 clinically evaluable children with bacteriologically documented AOM.

Conclusions

On the basis of bacteriologic outcome on Days 4 to 6 and clinical outcome on Days 12 to 15, we found that high dose amoxicillin/clavulanate (90/6.4 mg/kg/day) was highly efficacious in children with AOM, including those most likely to fail treatment, namely children < 24 months of age and those with infectious caused by PRSP.

---

### Diagnosis and management of acute otitis media in the urgent care setting [^113a45ZX]. Annals of Emergency Medicine (2002). Low credibility.

The prevalence of otitis media is increasing, which affects health care resource utilization across all segments, including the urgent care setting. One of the greatest challenges in the management of acute otitis media (AOM) is the effective treatment of cases caused by pathogens that are resistant to commonly used antibiotics. Whereas the production of beta-lactamases among strains of Haemophilus influenzae and Moraxella catarrhalis is an important consideration for antimicrobial therapy, the high prevalence of resistance to penicillin and other classes of antibiotics among strains of Streptococcus pneumoniae represents a greater clinical concern. The Centers for Disease Control and Prevention (CDC) recently convened the Drug Resistant S. pneumoniae Therapeutic Working Group to develop evidence-based recommendations for the treatment of AOM in an era of prevalent resistance. The recommendations from this group included amoxicillin as the preferred first-line drug because of the demonstrated activity against penicillin-intermediate and -resistant strains of S. pneumoniae, using higher dosages of up to 90 mg/kg per day in certain settings. For patients in whom initial treatment is unsuccessful after 3 days, the recommended agents included high-dose amoxicillin-clavulanate (for activity against beta-lactamase-producing pathogens), clindamycin, cefuroxime axetil, or 1 to 3 doses of intramuscular ceftriaxone. The principles set forth in these guidelines can assist the therapeutic decisionmaking process for practitioners in the urgent care setting.

---

### Trends in broad-spectrum antibiotic prescribing for children with acute otitis media in the United States, 1998–2004 [^113sygWB]. BMC Pediatrics (2009). Low credibility.

There were some aspects of the data that may limit the conclusions that can be drawn from our results. First, the NAMCS and NHAMCS survey format does not allow for direct linkage between diagnosis and medication. Even though we attempted to use a rigorous method for linking the antibiotic prescribed during a visit to an AOM diagnosis, it is possible that the antibiotics were actually prescribed for a different condition than was addressed in the visit. Second, as mentioned previously, multiple visits by the same individual are not accounted for because individual identifiers are not coded in NAMCS and NHAMCS. Lastly, we were unable to determine if high dose amoxicillin (80 to 90 mg/kg/day) was prescribed to children who received an amoxicillin prescription. High dose amoxicillin was recommended as first line treatment for AOM by a CDC consensus panel in 1999 due to concerns of drug-resistant Streptococcus pneumoniae. It is possible that the rate of prescribing of high dose amoxicillin, in keeping with these guidelines, increased despite the overall stable trend in amoxicillin prescribing.

The CDC has championed national efforts to address antibiotic overuse through education of healthcare providers and the public. And although overall pediatric antibiotic prescribing rates and visits for AOM have decreased, it is concerning that prescribing for AOM, now known to be coupled with a high likelihood of a broad-spectrum antibiotic prescription, has not. Perhaps the best means of avoiding unnecessary broad-spectrum antibiotics for AOM is to limit those children receiving any antibiotic prescription. In this regard, we support the national AOM practice guidelines that allow for the option of observation as the first-line treatment of uncomplicated AOM in children with mild disease. These guidelines have been further supported by recent, randomized, controlled trials in multiple settings as well as several older metaanalyses. Adherence to the guidelines would not only directly decrease antibiotic prescriptions for broad-spectrum and other agents, but perhaps, also indirectly, as more parents came to learn that a doctor's visit is not always necessary when their child's symptoms are mild.

---

### Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants [^116doz3F]. BMJ (2009). Excellent credibility.

Objective

To determine the long term effects of antibiotic treatment for acute otitis media in young children.

Design

Prospective three year follow-up study within the framework of a primary care based, double blind, randomised, placebo controlled trial.

Setting

53 general practices in the Netherlands.

Participants

168 children aged 6 months to 2 years with acute otitis media.

Interventions

Amoxicillin 40 mg/kg/day in three doses compared with placebo.

Main Outcome Measures

Recurrence of acute otitis media; referral to secondary care; ear, nose, and throat surgery.

Results

Acute otitis media recurred in 63% (47/75) of children in the amoxicillin group and in 43% (37/86) of the placebo group (risk difference 20%, 95% confidence interval 5% to 35%); 30% (24/78 amoxicillin; 27/89 placebo) of children in both groups were referred to secondary care, and 21% (16/78) of the amoxicillin group compared with 30% (27/90) of the placebo group had ear, nose, and throat surgery (risk difference -9%, -23% to 4%).

Conclusion

Recurrent acute otitis media occurred more often in the children originally treated with amoxicillin. This is another argument for judicious use of antibiotics in children with acute otitis media. Trial registration Netherlands Trial Register NTR1426.

---

### The diagnosis and management of acute otitis media [^111eTJjM]. Pediatrics (2013). Medium credibility.

Regarding medical management for acute otitis media, more specifically with respect to systemic antibiotics, indications, older children, AAFP/AAP 2013 guidelines recommend to initiate antibiotic therapy, or offer observation with close follow-up based on joint decision-making with the parent/caregiver, in ≥ 24 months old patients with AOM without severe signs or symptoms.

---

### The diagnosis and management of acute otitis media [^115y988r]. Pediatrics (2013). Medium credibility.

Initial antibiotic treatment failure in AOM — monitoring and next steps are as follows: When antibiotics are prescribed, clinical improvement should be noted within 48 to 72 hours; during the 24 hours after diagnosis symptoms may worsen slightly, then should begin to improve in the next 24 hours, and if initially febrile, temperature should decline within 48 to 72 hours. If the patient is not improved by 48 to 72 hours, reassess for another disease, concomitant viral infection, or resistance. Evidence on clinical–bacteriologic correlation is mixed, with some studies reporting good correlation ranging from 86% to 91% and others reporting sterile middle ear fluid in 42% to 49% of cases. A change in antibiotic may not be required in some children with mild persistent symptoms; however, in children with persistent, severe symptoms and unimproved otologic findings after initial treatment, the clinician may consider changing the antibiotic. If initially treated with amoxicillin and failed to improve, amoxicillin-clavulanate should be used; patients previously given amoxicillin-clavulanate or oral third-generation cephalosporins may receive intramuscular ceftriaxone (50 mg/kg), and in AOM unresponsive to initial antibiotics, a 3-day course of ceftriaxone has been shown to be better than a 1-day regimen.

---

### Clinical practice guideline: otitis media with effusion (update) [^111eJxRX]. Otolaryngology — Head and Neck Surgery (2016). Medium credibility.

Statement 8b — antibiotics for otitis media with effusion: Clinicians should recommend against using systemic antibiotics for treating OME. This is a strong recommendation against based on systematic review of randomized controlled trials (RCTs) and preponderance of harm over benefit.

---

### Single dose azithromycin for the treatment of uncomplicated otitis media [^111bs2aE]. The Pediatric Infectious Disease Journal (2004). Low credibility.

Three clinical trials have examined the efficacy and safety of single dose azithromycin (30 mg/kg) in children with uncomplicated acute otitis media (AOM). In the first trial, a small pilot study, the clinical and microbiologic efficacy of single dose azithromycin was comparable with that of 3-day azithromycin or single dose ceftriaxone. A second, non-comparative trial confirmed the clinical and microbiologic efficacy of the single dose regimen. The third study, a large double blind, double dummy trial, demonstrated comparable clinical success rates between single dose azithromycin and 10-day standard amoxicillin/clavulanate. The incidence of drug-related adverse events in patients treated with single dose azithromycin was low in all three trials and similar to rates that have been reported for other antimicrobial agents used for the treatment of patients with AOM. In the amoxicillin/clavulanate trial, compliance with single dose azithromycin was significantly better than with the amoxicillin/clavulanate regimen (P < 0.001). We conclude that a single dose of azithromycin (30 mg/kg) is safe and effective for the treatment of uncomplicated AOM in children.

---

### Amoxicillin [^111zGw1b]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of lower respiratory tract infections in both children (in patients ≤ 3 months) is up to 30 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptoms resolution

---

### Management of recurrent and persistent acute otitis media: new options with familiar antibiotics [^117Nosa3]. The Pediatric Infectious Disease Journal (2004). Low credibility.

Recurrent and persistent acute otitis media (AOM) is a common problem, affecting close to 20% of children in their first years of life. It presents a therapeutic challenge to physicians, particularly as beta-lactamase-producing Haemophilus influenzae, as well as penicillin- and, more recently, macrolide-resistant Streptococcus pneumoniae are often responsible for AOM in these patients. Intramuscular ceftriaxone (50 mg/kg, once daily for 3 days) has been shown to be effective in treating nonresponsive AOM, but there have been relatively few clinical trials exploring oral antibiotic regimens. Higher doses of commonly used antibiotics (amoxicillin-clavulanate ratio, 14:1 ratio and azithromycin 60 mg/kg divided into three equal once daily doses) have demonstrated high rates of clinical success. These studies will be discussed together with a review of the clinical and microbiologic characteristics of this disease. We will also address the impact that the pneumococcal conjugate vaccine may have on the microbiology of recurrent and persistent AOM.

---

### Trends in broad-spectrum antibiotic prescribing for children with acute otitis media in the United States, 1998–2004 [^111CXw1q]. BMC Pediatrics (2009). Low credibility.

We also noted that as broad-spectrum antibiotic prescribing increased, amoxicillin prescribing remain stable, despite the operant guideline for this time period recommending high dose amoxicillin as first-line therapy for most children. Of note, the study period ended before the most recent guidelines on AOM, recommending amoxicillin/clavulanate as the initial choice for children with severe infection, would have had a significant impact on amoxicillin prescribing. Encouragingly, we found a significant decrease in the proportion of patients receiving narrow-spectrum antibiotics other than amoxicillin from 1998 to 2004. These antimicrobials have been shown to be less effective options for AOM and are no longer recommended therapy in the United States.

We found that broad-spectrum prescribing was less likely in those children with ear pain and was not associated with age or fever; factors characteristic of more severe infections that might have justified broader coverage. Instead, significant associations were for the nonclinical factors of race, insurance status, geographical location, and ambulatory setting. Over-prescribing of antibiotics to pediatric white patients has been reported in another study. High antibiotic prescribing rates have been found in the South in other studies. And lower rates of nonrecommended (broad-spectrum) antibiotics for children with sore throats seen in emergency departments have been reported as well. In contrast, general practitioners in the Netherlands were more likely to overprescribe antibiotics, according to Dutch guidelines, to younger children who were more severely ill. Unfortunately, due to limitations in the data, we were unable to explore associations with other risk factors linked to the presence of bacterial species likely to be resistant to amoxicillin. These include attendance at child care and recent prescription (less than 30 days) of an antibiotic. However, there is no reason to believe that these factors would have changed significantly over the 7 year period.

---

### The diagnosis and management of acute otitis media [^112KSmBB]. Pediatrics (2013). Medium credibility.

Regarding medical management for acute otitis media, more specifically with respect to systemic antibiotics, indications, older children, AAFP/AAP 2013 guidelines recommend to ensure follow-up when observation is used as an initial strategy with the initiation of antibiotic therapy when the patient worsens or fails to improve within 48–72 hours of the onset of symptoms.

---

### The diagnosis and management of acute otitis media [^112QStUz]. Pediatrics (2013). Medium credibility.

Regarding medical management for acute otitis media, more specifically with respect to systemic antibiotics, indications, young children, AAFP/AAP 2013 guidelines recommend to initiate antibiotic therapy in ≥ 6 months old patients with AOM (bilateral or unilateral) with severe signs or symptoms, including:

- moderate or severe otalgia

- duration of otalgia ≥ 48 hours

- temperature > 39 °C.

---

### Management of acute otitis media by primary care physicians: trends since the release of the 2004 American Academy of Pediatrics / American Academy of Family Physicians clinical practice guideline [^1137w1m6]. Pediatrics (2007). Low credibility.

Objectives

In 2004, the American Academy of Pediatrics and the American Academy of Family Physicians released a clinical practice guideline on the management of acute otitis media that included endorsement of an observation option for selected cases and recommendations of specific antibiotics. We sought to describe primary care physicians' current management of acute otitis media to compare it with the guideline's recommendations and describe trends since 2004.

Design

We used a mail survey from March through June 2006 within the Slone Center Office-Based Research Network, a national practice-based pediatric research network.

Results

The response rate was 299 (62.7%) of 477. The observation option was considered reasonable by 83.3%, compared with 88.0% in 2004, and was used in a median of 15% of acute otitis media cases over the previous 3 months. The most common physician-identified barriers to the use of the observation option were parental reluctance (83.5%) and the cost and difficulty of follow-up of children who do not improve (30.9%). In terms of antibiotic choices for acute otitis media, agreement with the guideline's antibiotic recommendation for 4 common clinical scenarios was as follows: high-dose amoxicillin for acute otitis media with nonsevere symptoms (57.2%), high-dose amoxicillin-clavulanate for acute otitis media with severe symptoms (12.7%), high-dose amoxicillin-clavulanate for cases that failed to respond to amoxicillin (42.8%), and intramuscular ceftriaxone for cases that failed to respond to treatment with amoxicillin-clavulanate (16.7%). Each of these proportions declined from 2004.

Conclusions

Most primary care physicians accept the concept of an observation option for acute otitis media but use it only occasionally. Antibiotics prescribed for acute otitis media differ markedly from the guideline's recommendations, and the difference has increased since 2004.

---

### A randomized comparative study of levofloxacin versus amoxicillin / clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media [^1174ut1D]. The Pediatric Infectious Disease Journal (2008). Low credibility.

Background

The need for alternative antimicrobial therapy for recurrent and persistent acute otitis media (AOM) in children has raised interest in assessing the efficacy and safety of fluoroquinolones for treatment of these infections.

Methods

In an evaluator-blinded, active-comparator, noninferiority, multicenter study, children (6 months to < 5 years) were randomized 1:1 to receive levofloxacin (10 mg/kg twice daily) or amoxicillin/clavulanate (14:1; amoxicillin 45 mg/kg twice daily) for 10 days, with evaluations 4–6 days of therapy (visit 2), 2–5 days after completing therapy (visit 3), and 10–17 days after last dose (visit 4). Primary outcome was clinical cure at visit 3 based on resolution of clinical signs and symptoms of AOM.

Results

A total of 1650 children were randomized and 1305 were clinically evaluable at visit 3 (630 levofloxacin, 675 comparator). Clinical cure rates were 72.4% (456 of 630) in levofloxacin-treated and 69.9% (472 of 675) in amoxicillin/clavulanate-treated children. Cure rates were also similar for levofloxacin and comparator for each age group (≤ 24 months: 68.9% versus 66.2%; > 24 months: 76.9% versus 75.1%; respectively). Cure rates at visit 4 were 74.9% and 73.8% in levofloxacin and amoxicillin/clavulanate groups, respectively. The upper limits of the confidence intervals were less than the noninferiority margin of 10% indicating that levofloxacin treatment is noninferior to comparator treatment overall and in both infants (6 months to 2 years) and children 2–5 years. No differences between treatment groups regarding the frequency or type of adverse events were apparent.

Conclusions

Levofloxacin was not inferior to amoxicillin/clavulanate for the treatment of recurrent and/or persistent AOM in infants and children.

---

### Prognostic factors for treatment failure in acute otitis media [^112nBjM4]. Pediatrics (2017). Low credibility.

Background and Objectives

Antimicrobial treatment is effective in the management of acute otitis media (AOM), but approximately half of the children may recover without antimicrobial agents. By identifying patients who may not require antimicrobial treatment for the management of AOM, the use of antimicrobial agents could be substantially reduced. Our aim was to identify subgroups of children with AOM who would benefit most from antimicrobial treatment and children who could be suitable for initial observation.

Methods

This is a secondary analysis of randomized, double-blind, placebo-controlled trial. Children 6 to 35 months of age with AOM (N = 319) were randomly allocated to receive amoxicillin-clavulanate (40/5.7 mg/kg per day) or placebo for 7 days. Our primary outcome was time until treatment failure.

Results

Treatment failure occurred in 31.7% of all children. Older age (24–35 months) and peaked tympanogram at entry decreased the hazard for treatment failure (hazard ratio, 0.53; 95% confidence interval, 0.29 to 0.96; p = 0.04; and hazard ratio, 0.43; 95% CI, 0.21 to 0.88; p = 0.02, respectively). The rate difference for treatment failure between antimicrobial treatment and placebo groups was highest among children with severe bulging of the tympanic membrane (11.1% vs 64.1%; rate difference -53.0%; 95% CI, -73.5% to -32.4%), resulting in a number needed to treat of 1.9.

Conclusions

Children with severe bulging of the tympanic membrane seem to benefit most from antimicrobial treatment of AOM. On the other hand, children with peaked tympanogram (A and C curves) may be optimal candidates for initial observation.

---

### Clinical outcomes associated with amoxicillin treatment for acute otitis media in children [^113nNwhr]. Journal of the Pediatric Infectious Diseases Society (2024). Medium credibility.

Background

Acute otitis media (AOM) is the most common reason children are prescribed antibiotics. Bacteria that produce beta-lactamase are an increasingly frequent cause of AOM and may be resistant to amoxicillin, the currently recommended treatment for AOM. We aimed to evaluate the clinical outcomes of children treated with amoxicillin for AOM and assessed whether outcomes vary by infecting pathogen or beta-lactamase production.

Methods

205 children 6–35 months old diagnosed with AOM and prescribed amoxicillin were included. Bacterial culture and qualitative multiplex real-time polymerase chain reaction were performed on nasopharyngeal swabs collected at enrollment. Parents completed surveys assessing symptoms, antibiotic adherence, and potential adverse events. The primary outcome was treatment failure with amoxicillin. Secondary outcomes included recurrence, symptom improvement, resolution, and adverse drug events (ADE).

Results

8 children (5.4%) experienced treatment failure and 14 (6.8%) had recurrence. By day 5, 152 (74.1%) children had symptom improvement and 97 (47.3%) had resolution. Parents reported ADE for 56 (27.3%) children. Among 149 children who did not take any amoxicillin before enrollment, 98 (65.8%) had one or more beta-lactamase-producing bacteria. Common bacterial otopathogens were Moraxella catarrhalis (79, 53.0%), Streptococcus pneumoniae (51, 34.2%), Haemophilus influenzae (30, 20.1%), and Staphylococcus aureus (21, 14.1%). Treatment failure did not differ between children that did (5, 5.1%) and did not (3, 5.9%) have beta-lactamase-producing otopathogens (p = .05).

Conclusions

Among children diagnosed with AOM treated with amoxicillin, treatment failure was uncommon and did not differ by pathogen or beta-lactamase production. These data support guidance recommending amoxicillin despite an increasing prevalence of beta-lactamase-producing bacteria.

---

### Trends in broad-spectrum antibiotic prescribing for children with acute otitis media in the United States, 1998–2004 [^113PDUdr]. BMC Pediatrics (2009). Low credibility.

Conclusion

In conclusion, the prescribing of broad-spectrum antibiotics for AOM has increased dramatically from 1998 to 2004 and the trend occurred in the midst of the implementation of a national immunization program effective in decreasing the severity and incidence of this common pediatric infection. Physicians have increased their prescribing of broad-spectrum antibiotics for AOM without correlation to clinical factors such as age or severity of illness. If primary care physicians decide antibiotics are needed for AOM, prescribing amoxicillin as initial therapy is recommended for most children, especially with the reassurance of its effectiveness provided by PCV.

---

### The diagnosis and management of acute otitis media [^117QLcdx]. Pediatrics (2013). Medium credibility.

Amoxicillin-clavulanate versus placebo in acute otitis media — randomized trial outcomes report baseline age distribution, efficacy, and adverse events: in the treatment group, 135 of 161 patients (84%) were younger than 24 months versus 124 of 158 (78%) in placebo; treatment failure occurred in 18.6% versus 44.9% (NNT = 3.8, P < .001), rescue treatment was needed in 6.8% versus 33.5% (P < .001), contralateral AOM developed in 8.2% versus 18.6% (P = .007), and use of analgesic or antipyretic medicine was 84.2% versus 85.9%. Parents of child care attendees on placebo missed more days of work (P = .005); clinical failure in unilateral AOM was 17.2% versus 42.7% and in bilateral AOM 21.7% versus 46.3%, with day 8 failures 17.2% versus 42.7% (unilateral) and 21.7% vs 46.3% (bilateral). Adverse events occurred in 52.8% versus 36.1% (P = .003), overall condition and tympanic membrane appearance favored antibiotics at end of treatment (P < .001), and two placebo recipients developed severe infection (pneumococcal bacteremia or radiographically confirmed pneumonia).

---

### The diagnosis and management of acute otitis media [^111f53kK]. Pediatrics (2013). Medium credibility.

Acute otitis media — pathogen susceptibility considerations informing empiric therapy: High-dose amoxicillin–clavulanate achieved eradication of Streptococcus pneumoniae (96%) from the middle ear at days 4 to 6 in one study; current data indicate 58% to 82% of Haemophilus influenzae isolates are susceptible to regular- and high-dose amoxicillin, while 100% of Moraxella catarrhalis from the upper respiratory tract are β-lactamase–positive but remain susceptible to amoxicillin–clavulanate, and AOM attributable to M catarrhalis rarely progresses to acute mastoiditis or intracranial infections.

---

### The diagnosis and management of acute otitis media [^112w6nwW]. Pediatrics (2013). Medium credibility.

Acute otitis media (AOM) randomized trial in children 6 to 23 months — amoxicillin-clavulanate versus placebo — reported symptom resolution, failure, and adverse events with quantified effects. Included in the study were 291 patients 6 to 23 months of age: 144 in the antibiotic group and 147 in the placebo group. Initial resolution (AOM-SOS score 0 or 1) with amoxicillin-clavulanate occurred in 35% by day 2, 61% by day 4, and 80% by day 7, versus 28%, 54%, and 74% with placebo (P = .14). For sustained resolution (second of 2 successive AOM-SOS 0 or 1), values were 20% by day 2, 41% at day 4, and 67% at day 7 with amoxicillin-clavulanate versus 14%, 36%, and 53% with placebo (P = .04). Treatment failure occurred by day 4 to 5 in 4% with antimicrobial treatment versus 23% with placebo (P < .001) and at day 10 to 12 in 16% versus 51% (NNT = 2.9, P < .001). By day 10 to 12, clinical failure in unilateral AOM was 9% with amoxicillin-clavulanate versus 41% with placebo (RD, 32%; NNT = 3), and in bilateral AOM was 23% versus 60% (RD, 37%; NNT = 3). Most common adverse events were diarrhea (25% vs 15%; p = 0.05) and diaper dermatitis (51% vs 35%; p = 0.008), and one placebo recipient developed mastoiditis.

---

### The diagnosis and management of acute otitis media [^1146Yxup]. Pediatrics (2013). Medium credibility.

Antibiotic prophylaxis for recurrent acute otitis media (AOM) — magnitude and limits — Long-term, low-dose antibiotic use, referred to as antibiotic prophylaxis or chemoprophylaxis, has been used to treat children with recurrent AOM to prevent subsequent episodes. A 2006 Cochrane review analyzed 16 studies and found such use prevented 1.5 episodes of AOM per year and reduced by half the number of episodes during treatment; randomized placebo-controlled trials reported a decrease of 0.09 episodes per month, approximately 0.5 to 1.5 AOM episodes per year for 95% of children, with an estimated 5 children needing treatment for 1 year to prevent 1 episode of OM, and the effect may be more substantial for children with 6 or more AOM episodes in the preceding year. This decrease occurred only while prophylactic antibiotic was being given and a 6-month course does not have longer-lasting benefit after cessation; Teele showed no differences versus placebo in AOM recurrences or persistence of OME. Antibiotic prophylaxis is not appropriate for children with long-term MEE or infrequent episodes of AOM, and any small reduction must be weighed against cost, potential adverse effects such as allergic reaction and gastrointestinal consequences like diarrhea, and contribution to bacterial resistance.

---

### Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis [^11587PSf]. The Annals of Pharmacotherapy (2010). Low credibility.

Background

Macrolide antibiotics are often used to treat children with acute otitis media (AOM); however, the 2004 American Academy of Pediatrics (AAP) and American Academy of Family Physicians guidelines recommend against their use in patients without history of a type I allergic reaction to penicillins.

Objective

To evaluate via meta-analysis the comparative efficacy of amoxicillin or amoxicillin/clavulanate to that of macrolide antibiotics in the treatment of children with AOM.

Methods

A systematic literature search of MEDLINE, EMBASE, and International Pharmaceutical Abstracts was conducted from the earliest available date through September 2008. We used the following MeSH and key words: amoxicillin, amoxicillin/clavulanate, Augmentin, azithromycin, ceftriaxone, clarithromycin, macrolides, AND media, otitis media, and effusion. Included studies were randomized, blinded, and controlled trials evaluating guideline-recommended antibiotics (amoxicillin or amoxicillin/clavulanate) compared to macrolide antibiotics (azithromycin or clarithromycin) in AOM in children. The primary outcome assessed was clinical failure measured between days 10 and 16 after starting antibiotic therapy. Results are reported as relative risks (RRs) with 95% confidence intervals and were calculated using a random-effects model.

Results

A total of 10 trials (N = 2766) evaluating children 6 months-15 years old were included in the meta-analysis. Upon meta-analysis, the use of macrolide antibiotics was associated with an increased risk of clinical failure (RR 1.31 [95% CI 1.07 to 1.60]; p = 0.008) corresponding to a number needed to harm of 32. Upon safety analysis, rates of any adverse reaction (RR 0.74 [95% CI 0.60 to 0.90]; p = 0.003) and diarrhea (RR 0.41 [95% CI 0.32 to 0.52]; p < 0.0001) were significantly lower in the macrolide group.

Conclusions

The meta-analysis suggests that patients treated with macrolides for AOM may be more likely to have clinical failures. As such, it supports the current AAP AOM recommendation that macrolides be reserved for patients who can not receive amoxicillin or amoxicillin/clavulanate.

---

### Adverse events of antibiotics used to treat acute otitis media in children: a systematic meta-analysis [^112DyNQC]. The Journal of Pediatrics (2019). Medium credibility.

Objective

To characterize the incidence of adverse events (AEs) associated with antibiotics used to treat acute otitis media in children.

Study Design

We searched MEDLINE for studies conducted between January 1, 1966, and August 25, 2018. Two authors independently assessed potential studies and extracted the data. We included published randomized controlled trials, cross-sectional studies, and cohort studies that evaluated the incidence of diarrhea, generalized rash, diaper rash, and candidal diaper dermatitis associated with the use of amoxicillin, amoxicillin/clavulanate, azithromycin, cefdinir, and placebo in children with acute otitis media.

Results

We included 82 studies in the meta-analysis. The incidence of diarrhea, listed from lowest to highest, was azithromycin (2.2%), placebo (6.9%), low-dose amoxicillin (8.7%), cefdinir (13.0%), high-dose amoxicillin (13.8%), and high-dose amoxicillin/clavulanate (18.9%). The incidence of generalized rash, listed from lowest to highest, was azithromycin (1.4%), placebo (2.3%), low-dose amoxicillin (2.9%), high-dose amoxicillin/clavulanate (4.9%), and high-dose amoxicillin (6.5%). In studies of low-dose amoxicillin, we found a higher incidence of diarrhea in studies that used daily diaries to collect information about diarrhea and a lower incidence of generalized rash in studies that reported only rashes judged to be secondary to antibiotic use.

Conclusions

The incidence of AEs varies widely depending on which antibiotic is used and how the information on AEs was collected or reported. The AEs rates reported here may be helpful to clinicians when choosing an antibiotic to treat acute otitis media.

---

### Amoxicillin [^117Gr2wr]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of acute bacterial rhinosinusitis in both children (in patients ≤ 3 months) is up to 30 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptoms resolution

---

### Reducing the frequency of acute otitis media by individualized care [^1172ndJU]. The Pediatric Infectious Disease Journal (2013). Low credibility.

Objective

We sought to determine if use of more stringent diagnostic criteria for acute otitis media (AOM) than currently advocated by the American Academy of Pediatrics, tympanocentesis and pathogen-specific antibiotic treatment (individualized care) would result in reducing the incidence of recurrent AOM and consequent tympanostomy tube surgery.

Methods

A 5-year longitudinal, prospective study in Rochester, NY, was conducted from July 2006 to July 2011 involving 254 individualized care children. When this individualized care group developed symptoms of AOM, strict diagnostic criteria were applied and a tympanocentesis was performed. Pathogen resistance to empiric high-dose amoxicillin/clavulanate (80 mg/kg of amoxicillin component) caused a change in antibiotic to an optimized choice. Legacy controls (n = 208) were diagnosed with the same diagnostic criteria by the same physicians as the individualized care group and received the same empiric amoxicillin/clavulanate (80 mg/kg of amoxicillin component) but no tympanocentesis or change in antibiotic. Community control children (n = 1020) were diagnosed according to current American Academy of Pediatrics guidelines and treated with high-dose amoxicillin (80 mg/kg) without tympanocentesis as guideline recommended.

Results

5.9% of children of the individualized care group compared with 14.4% of Legacy controls and 27.3% of community controls became otitis prone, defined as 3 episodes of AOM within a 6-month time span or 4 AOM episodes within a 12-month time span (P < 0.0001). 2.4% of the individualized care group compared with 6.3% of Legacy controls, and 14.8% of community controls received tympanostomy tubes (P < 0.0001).

Conclusions

Individualized care of AOM significantly reduces the frequency of AOM and tympanostomy tube surgery. Use of strict diagnostic criteria for AOM and empiric antibiotic treatment using evidence-based knowledge of circulating otopathogens and their antimicrobial susceptibility profile also produces improved outcomes.

---

### Amoxicillin [^112yqKkQ]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of lower respiratory tract infections in both children (in patients > 3 months) is 40 mg/kg PO daily, in 3 divided doses, until 48–72 hours of symptoms resolution

---

### Evidence assessment of management of acute otitis media: I. the role of antibiotics in treatment of uncomplicated acute otitis media [^116AVPji]. Pediatrics (2001). Low credibility.

Context

In 1995, > 5 million episodes of acute otitis media (AOM) accounted for $3 billion in health care expenditures.

Objectives

To synthesize the literature on the natural history of AOM, the effectiveness of antibiotic treatment in uncomplicated AOM, and the relative effectiveness of specific antibiotic regimens.

Data Sources

Seven electronic databases for articles published between 1966 and March 1999 and reference lists in proceedings, published articles, reports, and guidelines.

Study Selection

Two physicians independently assessed each article. Studies addressing AOM in children 4 weeks to 18 years old were included; those addressing children with immunodeficiencies or craniofacial abnormalities were excluded. Randomized, controlled trials (RCTs) were used to assess antibiotic effectiveness, and RCTs and cohort studies were used to assess the natural history of AOM. Among the 3491 citations identified, 80 (2.3%) met our inclusion criteria.

Data Extraction

Two physicians independently abstracted data and assessed the quality of studies using a validated scale for RCTs and 8 quality components for cohort studies.

Data Synthesis

Random-effects estimates of pooled absolute rate differences of outcomes were derived, and heterogeneity of both the rates and rate differences was assessed. Children with AOM not treated with antibiotics experienced a 1- to 7-day clinical failure rate of 19% (95% confidence interval: 0.10–0.28) and few suppurative complications. When patients were treated with amoxicillin, the 2- to 7-day clinical failure rate was reduced to 7%, a 12% (95% confidence interval: 0.04–0.20) reduction. Adverse effects, primarily gastrointestinal, were more common among children on cefixime than among those on ampicillin or amoxicillin. They were also more common among children on amoxicillin-clavulanate than among those on azithromycin.

Conclusions

The majority of uncomplicated cases of AOM resolve spontaneously without apparent suppurative complications. Ampicillin or amoxicillin confers a limited therapeutic benefit. There is no evidence to support any particular antibiotic regimens as more effective at relieving symptoms. Certain antibiotics are more likely than others to cause diarrhea and other adverse events.

---

### Shortened antimicrobial treatment for acute otitis media in young children [^111KtmPc]. The New England Journal of Medicine (2016). Excellent credibility.

Background

Limiting the duration of antimicrobial treatment constitutes a potential strategy to reduce the risk of antimicrobial resistance among children with acute otitis media.

Methods

We assigned 520 children, 6 to 23 months of age, with acute otitis media to receive amoxicillin-clavulanate either for a standard duration of 10 days or for a reduced duration of 5 days followed by placebo for 5 days. We measured rates of clinical response (in a systematic fashion, on the basis of signs and symptomatic response), recurrence, and nasopharyngeal colonization, and we analyzed episode outcomes using a noninferiority approach. Symptom scores ranged from 0 to 14, with higher numbers indicating more severe symptoms.

Results

Children who were treated with amoxicillin-clavulanate for 5 days were more likely than those who were treated for 10 days to have clinical failure (77 of 229 children [34%] vs. 39 of 238 [16%]; difference, 17 percentage points [based on unrounded data]; 95% confidence interval, 9 to 25). The mean symptom scores over the period from day 6 to day 14 were 1.61 in the 5-day group and 1.34 in the 10-day group (P = 0.07); the mean scores at the day-12-to-14 assessment were 1.89 versus 1.20 (P = 0.001). The percentage of children whose symptom scores decreased more than 50% (indicating less severe symptoms) from baseline to the end of treatment was lower in the 5-day group than in the 10-day group (181 of 227 children [80%] vs. 211 of 233 [91%], P = 0.003). We found no significant between-group differences in rates of recurrence, adverse events, or nasopharyngeal colonization with penicillin-nonsusceptible pathogens. Clinical-failure rates were greater among children who had been exposed to three or more children for 10 or more hours per week than among those with less exposure (P = 0.02) and were also greater among children with infection in both ears than among those with infection in one ear (P < 0.001).

Conclusions

Among children 6 to 23 months of age with acute otitis media, reduced-duration antimicrobial treatment resulted in less favorable outcomes than standard-duration treatment; in addition, neither the rate of adverse events nor the rate of emergence of antimicrobial resistance was lower with the shorter regimen. (Funded by the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources; ClinicalTrials.gov number, NCT01511107 .).

---

### Amoxicillin [^113JJesN]. FDA (2024). Medium credibility.

The dosage of amoxicillin PO for treatment of lower respiratory tract infections in both children (in patients > 3 months) is 45 mg/kg PO daily, in 2 divided doses, until 48–72 hours of symptoms resolution

---

### Small children receive large doses, while large children receive low doses of amoxicillin per kg [^117Rf8Ae]. Clinical Pediatrics (2025). Medium credibility.

Purpose

With increasing pneumococcal penicillin resistance, physicians treat pneumococcal infections with high-dose amoxicillin (80–90 mg/kg/d). High-dose amoxicillin approaches adult doses which makes clinicians reluctant to exceed "adult doses". This study examines the disparity of amoxicillin dosing between the ages of children.

Methods

A retrospective chart review of 5503 children prescribed amoxicillin regardless of diagnosis. The final cohort consisted of 3620 encounters with infections that align with recommendations of high-dose amoxicillin.

Results

Linear regression demonstrated a significant negative correlation between age/dose (mg/kg/d) and weight/dose (mg/kg/d). Larger children are prescribed declining doses in mg/kg/d, so most patients above 60 kg are dosed at less than 40 mg/kg/d. Children 6 years and under cluster around the 80 mg/kg/d dose.

Conclusions

Older children receiving a lower than recommended dose per kilogram of amoxicillin for conditions that require high-dose amoxicillin. There is a disparity in the dosing of amoxicillin between age/weight categories. Article summaryA chart review of 3620 pediatric patient encounters prescribed amoxicillin. After controlling for weight, as age and weight increases, the dose of amoxicillin prescribed decreases. Children are reaching the adult maximum dose right after they surpass 15 kg. What is known on this subject: An Amoxicillin guideline shift to 80 to 90 mg/kg/d for treating pneumococcal infections in 2014. This was due to increasing intermediate penicillin resistance. Obesity results in children reaching the "maximum" doses at younger ages as well. What this study adds: There is a disparity is amoxicillin dosing among the pediatric population, are small children getting too much amoxicillin, or are larger children getting too little? Children are also reaching the adult maximum dose at low weights, such as 20 kg. Deidentified individual participant data will not be made available.

---

### Amoxicillin and clavulanate potassium (Augmentin) [^1128n4Kg]. FDA (2025). Medium credibility.

14.2 Acute Bacterial Otitis Media and Diarrhea in Pediatric Patients

One US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of AUGMENTIN for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of AUGMENTIN for 10 days in the treatment of acute otitis media. Only the suspension formulations were used in this trial. A total of 575 pediatric patients (aged 2 months to 12 years) were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., greater than or equal to 84%) per treatment group. Otitis media‑specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow‑up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow‑up visit (defined as 22 to 28 days post‑completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87% (n equals 265) and 82% (n equals 260) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. At follow‑up, 67% (n equals 249) and 69% (n equals 243) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively.

---

### Trends in otitis media treatment failure and relapse [^113HdiB5]. Pediatrics (2008). Low credibility.

Objectives

The goals were to describe trends in acute otitis media, treatment failure, and relapse and in high-dose amoxicillin use and to determine whether treatment of acute otitis media with high-dose amoxicillin was associated with treatment failure or relapse.

Methods

We conducted a retrospective study of acute otitis media visits made between 1996 and 2004 by children 2 months to 12 years of age in a large group practice, using computerized data. We defined acute otitis media as an otitis media visit with antibiotics dispensed (preceded by 30 days without otitis media visits), treatment failure as initiation of treatment with a second antibiotic before the first prescription was finished, and relapse as initiation of antibiotic treatment after the first prescription was finished but within 30 days after the index acute otitis media episode. The primary independent measure was high-dose amoxicillin (> 70 mg/kg per day). We evaluated changes over time and determined whether high-dose amoxicillin use was associated with otitis media treatment failure or relapse.

Results

We identified 111,335 acute otitis media visits over a 9-year period. The incidence of acute otitis media decreased from 385.1 visits per 1000 enrollees in 1996 to 188.8 visits per 1000 enrollees in 2004. The proportion of acute otitis media visits treated with high-dose amoxicillin increased from 1.7% in 1996 to 41.9% in 2004. Both otitis media treatment failure and relapse rates decreased from 1996 to 2004 (from 3.9% to 2.6% and from 9.2% to 8.9%, respectively). The odds of treatment failure or relapse did not differ between acute otitis media episodes treated with high-dose and low-dose amoxicillin.

Conclusions

During the past decade, acute otitis media, treatment failure, and relapse became less common and high-dose amoxicillin use increased. However, high-dose amoxicillin treatment did not reduce the risk of individual infections resulting in adverse outcomes.

---

### Amoxicillan and clavulanate potassium [^117Q27Gn]. FDA (2014). Low credibility.

8.4 Pediatric Use

The safety and effectiveness of amoxicillin and clavulanate potassium powder for oral suspension and chewable tablets have been established in pediatric patients. Use of amoxicillin and clavulanate potassium tablets in pediatric patients is supported by evidence from studies of amoxicillin and clavulanate potassium tablets in adults with additional data from a study of amoxicillin and clavulanate potassium powder for oral suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies (14.2)].

Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of amoxicillin and clavulanate potassium should be modified in pediatric patients aged < 12 weeks (< 3 months) [see Dosage and Administration (2.2)].

8.5 Geriatric Use

Of the 3,119 patients in an analysis of clinical studies of amoxicillin and clavulanate potassium, 32% were ≥ 65 years old, and 14% were ≥ 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6 Dosing in Renal Impairment

Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR < 30 mL/min). See Patients with Renal Impairment (2.3) for specific recommendations in patients with renal impairment.

---

### Assessment of emergency department antibiotic discharge prescription dosing errors for pediatric patients in a community hospital health system [^114HK1sd]. Pediatric Emergency Care (2020). Medium credibility.

Objectives

We quantify and describe emergency department antibiotic discharge prescription dosing errors for pediatric patients in a community hospital health system.

Methods

This was a retrospective chart review evaluating emergency department discharge prescriptions written between July 1, 2014, and June 30, 2015. Pediatric patients who received a prescription for an oral antibiotic were included in error analysis if they had a weight updated in the electronic medical record during the encounter. We used a predefined threshold of +10% variance from the recommended dose to quantify error. Prescriber, environmental, and antibiotic specific data were also collected to identify variables associated with high incidence of error.

Results

Among the 1934 prescriptions included in our error analysis, we detected 776 (40%) dosing errors. Of the prescriptions reviewed, 288 (15%) contained an overdosing error and 488 (25%) contained an underdosing error. There were 208 underdosing errors written for amoxicillin to treat acute otitis media. These errors represented 43% of the total underdosing errors and had a greater magnitude of variance from the recommended dose compared with overall underdosing errors.

Conclusions

Underdosing of amoxicillin in acute otitis media was a dosing error that occurred frequently throughout our community health system. Further research is needed to identify the clinical impact these errors have on pediatric patients.

---

### Amoxicillin and clavulante potassium (Augmentin) [^114AynSJ]. FDA (2010). Low credibility.

The dosage of amoxicillin / clavulanate potassium PO for treatment of acute otitis media in both children (in patients ≥ 3 months) is 45 mg/kg PO BID (200/28.5 mg dosing formulation)

---

### Knowledge and practices relating to the 2004 acute otitis media clinical practice guideline: a survey of practicing physicians [^115FsrYS]. The Pediatric Infectious Disease Journal (2006). Low credibility.

Objective

To identify primary care physicians' familiarity with the 2004 acute otitis media (AOM) clinical practice guideline and to compare their practices with its recommendations.

Design

Mail survey October through December 2004 to all active physician members of the Slone Center Office-based Research Network, a national, practice-based, pediatric research network.

Results

The response rate was 276 of 469 (58.8%). Overall, 90.5% had read the guideline or summaries of it. Pneumatic otoscopy was always used by 16.2%, used half the time or more by 23.1%, used less than half the time by 34.6% and never used by 26.2%. Observation is considered a reasonable option for some AOM cases by 88.0% and, over the previous 3 months, these physicians used observation a median of 10% of the time (25th and 75th percentiles, 5% and 25%, respectively). In terms of concern that the observation option may increase AOM complications, 75.6% were not at all or only slightly concerned; 24.4% were moderately or very concerned. In general, these physicians have altered their antibiotic prescribing practices for AOM towards the guideline's recommendations since its publication. However, antibiotic choices deviated most widely from the guideline in cases of AOM with severe illness, where only 17.9% follow the recommendation for high-dose amoxicillin-clavulanate, and in cases of children who fail treatment with amoxicillin-clavulanate, where only 27.7% favor the recommended intramuscular ceftriaxone.

Conclusions

Most physicians in this survey are familiar with the AOM guideline, but many do not follow its diagnostic and antibiotic recommendations. Observation for selected cases is acceptable to most of these physicians and is currently used in a small proportion of cases.

---

### Antibiotics for acute otitis media in children [^1137FsEi]. The Cochrane Database of Systematic Reviews (2015). Low credibility.

Background

Acute otitis media (AOM) is one of the most common diseases in early infancy and childhood. Antibiotic use for AOM varies from 56% in the Netherlands to 95% in the United States, Canada and Australia. This is an update of a Cochrane review first published in The Cochrane Library in Issue 1, 1997 and previously updated in 1999, 2005, 2009 and 2013.

Objectives

To assess the effects of antibiotics for children with AOM.

Search Methods

We searched CENTRAL (2015, Issue 3), MEDLINE (1966 to April week 3, 2015), OLDMEDLINE (1958 to 1965), EMBASE (January 1990 to April 2015), Current Contents (1966 to April 2015), CINAHL (2008 to April 2015) and LILACS (2008 to April 2015).

Selection Criteria

Randomised controlled trials (RCTs) comparing 1) antimicrobial drugs with placebo and 2) immediate antibiotic treatment with expectant observation (including delayed antibiotic prescribing) in children with AOM.

Data Collection and Analysis

Two review authors independently assessed trial quality and extracted data.

Main Results

For the review of antibiotics against placebo, 13 RCTs (3401 children and 3938 AOM episodes) from high-income countries were eligible and had generally low risk of bias. The combined results of the trials revealed that by 24 hours from the start of treatment, 60% of the children had recovered whether or not they had placebo or antibiotics. Pain was not reduced by antibiotics at 24 hours (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.78 to 1.01) but almost a third fewer had residual pain at two to three days (RR 0.70, 95% CI 0.57 to 0.86; number needed to treat for an additional beneficial outcome (NNTB) 20). A quarter fewer had pain at four to seven days (RR 0.76, 95% CI 0.63 to 0.91; NNTB 16) and two-thirds fewer had pain at 10 to 12 days (RR 0.33, 95% CI 0.17 to 0.66; NNTB 7) compared with placebo. Antibiotics did reduce the number of children with abnormal tympanometry findings at two to four weeks (RR 0.82, 95% CI 0.74 to 0.90; NNTB 11), at six to eight weeks (RR 0.88, 95% CI 0.78 to 1.00; NNTB 16) and the number of children with tympanic membrane perforations (RR 0.37, 95% CI 0.18 to 0.76; NNTB 33) and halved contralateral otitis episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11) compared with placebo. However, antibiotics neither reduced the number of children with abnormal tympanometry findings at three months (RR 0.97, 95% CI 0.76 to 1.24) nor the number of children with late AOM recurrences (RR 0.93, 95% CI 0.78 to 1.10) when compared with placebo. Severe complications were rare and did not differ between children treated with antibiotics and those treated with placebo. Adverse events (such as vomiting, diarrhoea or rash) occurred more often in children taking antibiotics (RR 1.38, 95% CI 1.19 to 1.59; number needed to treat for an additional harmful outcome (NNTH) 14). Funnel plots do not suggest publication bias. Individual patient data meta-analysis of a subset of included trials found antibiotics to be most beneficial in children aged less than two years with bilateral AOM, or with both AOM and otorrhoea. For the review of immediate antibiotics against expectant observation, five trials (1149 children) from high-income countries were eligible and had low to moderate risk of bias. Four trials (1007 children) reported outcome data that could be used for this review. From these trials, data from 959 children could be extracted for the meta-analysis of pain at three to seven days. No difference in pain was detectable at three to seven days (RR 0.75, 95% CI 0.50 to 1.12). One trial (247 children) reported data on pain at 11 to 14 days. Immediate antibiotics were not associated with a reduction in the number of children with pain (RR 0.91, 95% CI 0.75 to 1.10) compared with expectant observation. Additionally, no differences in the number of children with abnormal tympanometry findings at four weeks, tympanic membrane perforations and AOM recurrence were observed between groups. No serious complications occurred in either the antibiotic or the expectant observation group. Immediate antibiotics were associated with a substantial increased risk of vomiting, diarrhoea or rash compared with expectant observation (RR 1.71, 95% CI 1.24 to 2.36; NNTH 9). Results from an individual patient data meta-analysis including data from six high-quality trials (1643 children) that were also included as individual trials in our review showed that antibiotics seem to be most beneficial in children younger than two years of age with bilateral AOM (NNTB 4) and in children with both AOM and otorrhoea (NNTB 3).

Authors' Conclusions

This review reveals that antibiotics have no early effect on pain, a slight effect on pain in the days following and only a modest effect on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to four weeks and at six to eight weeks compared with placebo in children with AOM. In high-income countries, most cases of AOM spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children treated with antibiotics one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if antibiotics were withheld. Therefore clinical management should emphasise advice about adequate analgesia and the limited role for antibiotics. Antibiotics are most useful in children under two years of age with bilateral AOM, or with both AOM and otorrhoea. For most other children with mild disease in high-income countries, an expectant observational approach seems justified.

---

### Amoxicillin and clavulante potassium (Augmentin) [^116arxrG]. FDA (2010). Low credibility.

The dosage of amoxicillin / clavulanate potassium PO for treatment of acute otitis media in both children (in patients ≥ 3 months) is 40 mg/kg PO TID (125/31.25 mg dosing formulation)

---

### Otitis media [^117N8kDP]. Pediatric Clinics of North America (2013). Low credibility.

Acute otitis media (AOM) is diagnosed based on visualization of a full or bulging tympanic membrane with middle ear effusion. The distribution of bacteria causing AOM in North America under the influence of pneumococcal conjugate vaccination and antibiotic selection pressure has resulted in a predominance of β-lactamase-producing Haemophilus influenzae followed by penicillin-resistant Streptococcus pneumoniae. Although guidelines continue to endorse amoxicillin as the preferred treatment, amoxicillin/clavulanate in high dosage would be the preferred treatment based on the otopathogen mix currently. Antibiotic prophylaxis has fallen into disfavor as a preventative strategy for AOM recurrences.

---

### The diagnosis and management of acute otitis media [^113y75pc]. Pediatrics (2013). Medium credibility.

Regarding patient education for acute otitis media, more specifically with respect to assessment of treatment response, AAFP/AAP 2013 guidelines recommend to reassess patients in whom symptoms worsen or fail to respond to initial antibiotic treatment within 48–72 hours, and determine whether a change in therapy is needed.

---

### Pediatric ear, nose, and throat emergencies [^1144gKTe]. Pediatric Clinics of North America (2006). Low credibility.

Acute otitis media is the most common infection for which antibiotics are prescribed in children, resulting in more than 20 million antibiotic prescriptions annually. New practice guidelines published by the American Academy of Pediatrics and the American Academy of Family Physicians call for the judicious use of antibiotics in view of increasing antibiotic resistance and the unclear necessity of the use of antibiotics in children with uncomplicated acute otitis media. This article reviews those guidelines, several other common ear, nose, and throat entities, including sinusitis and dental emergencies, and current strategies in diagnosis and treatment.

---

### Amoxicillin and clavulanate potassium (Augmentin ES-600) [^111EzxRD]. FDA (2024). Medium credibility.

Animal Data

Reproduction studies performed in pregnant rats and mice given amoxicillin and clavulanate (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to amoxicillin and clavulanate. The amoxicillin doses in rodents (based on body surface area and assuming a 20 kg child) were approximately 2 times (rats) or equal to (mice) the recommended clinical AUGMENTIN ES-600 dose of 90/6.4 mg/kg/day. For clavulanate, these dose multiples were approximately 15 times and 7.5 times the recommended daily dose of AUGMENTIN ES-600.

8.2 Lactation

Risk Summary

Data from a published clinical lactation study report that amoxicillin is present in human milk. There are reports of diarrhea, irritability, and rash in infants exposed to amoxicillin and clavulanate through breast milk; therefore, infants exposed to AUGMENTIN ES-600 should be monitored for these symptoms. There are no data on the effects of amoxicillin and clavulanate on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AUGMENTIN ES-600 and any potential adverse effects on the breastfed child from AUGMENTIN ES-600 or from the underlying maternal condition.

8.4 Pediatric Use

Acute Otitis Media

The safety and effectiveness of AUGMENTIN ES-600 have been established in pediatric patients aged 3 months to 12 years weighing less than or equal to 40 kg, for the treatment of acute otitis media, and the information on this use is discussed throughout the labeling.

The safety and effectiveness of AUGMENTIN ES-600 in pediatric patients younger than 3 months of age have not been established.

The safety and effectiveness of Augmentin ES-600 have not been established in pediatric patients aged 3 months to 12 years weighing more than 40 kg.

Acute Bacterial Sinusitis

The safety and effectiveness of AUGMENTIN ES-600 have been established for the treatment of pediatric patients (3 months to 12 years of age) with acute bacterial sinusitis. This use is supported by evidence from adequate and well-controlled studies of AUGMENTIN XRTM Extended Release Tablets in adults with acute bacterial sinusitis, studies of AUGMENTIN ES-600 in pediatric patients with acute otitis media, and by similar pharmacokinetics of amoxicillin and clavulanate in pediatric patients taking AUGMENTIN ES-600 [see Clinical Pharmacology (12)] and adults taking AUGMENTIN XR.

---

### Standard-dose amoxicillin for acute otitis media… [^1174e5Vu]. AAFP (2005). Low credibility.

Current guidelines recommend treatment of high-dose amoxicillin for children with acute otitis media who are at high risk for infection with non-susceptible. Streptococcus pneumoniae. This includes all patients who are younger than two years, attend day care, or have recently been exposed to antibiotics. High-dose amoxicillin may not be needed if NSSP prevalence is low in the local area. However, prevalence data on NSSP is limited. Garbutt and colleagues used data from nasopharyngeal cultures to estimate the prevalence of NSSP in one city, and to develop community-specific treatment guidelines based on local susceptibility. Patients from seven pediatric offices were enrolled in the study; the inclusion criteria were age younger than seven years and a new diagnosis of AOM or one of several other upper respiratory infections. A posterior nasopharyngeal swab was obtained from each child.

Minimum inhibitory concentrations were then measured on. Of the 212 participating children, 70 had nonspecific upper respitory infection and 58 had AOM, the most frequent diagnoses. Twenty-nine of the children with AOM had positive nasopharyngeal swabs, as did 11 of those with otitis media with effusion, eight of those with acute sinusitis, and 30 of those with URI. In this study population, the authors calculate, standard-dose amoxicillin would have been effective in most patients treated for AOM. No more than an estimated 3 percent would have failed treatment. This percentage may in reality be even less because, among other reasons, nasopharyngeal carriage overestimates the presence of the organism in the middle ear. the authors conclude that treating the local population with standard-dose amoxicillin would be adequate, with high-dose treatment reserved for day-care attendees.

Although nasopharyngeal carriage does not correlate perfectly with middle ear isolates, this study demonstrates that it is relatively easy to measure local prevalence of NSSP and derive treatment recommendations accordingly. Still needed are accurate determinations of amoxicillin resistance and more information regarding the impact of pneumococcal conjugate vaccine on NSSP prevalence.

---

### Developing community-specific recommendations for first-line treatment of acute otitis media: is high-dose amoxicillin necessary? [^113KUn8n]. publications.aap.org (2025). Medium credibility.

Objectives. National recommendations are to use high-dose amoxicillin to treat uncomplicated acute otitis media in children who are at high risk for infection with nonsusceptible Streptococcus pneumoniae. However, high-dose treatment may not be necessary if the local prevalence of NSSP is low. The objective of this study was to estimate the local prevalence of NSSP in children with acute upper respiratory illnesses and to develop community-specific recommendations for first-line empiric treatment of AOM. Methods. We conducted a cross-sectional prevalence study in the offices of 7 community pediatricians in St Louis, Missouri. S pneumoniae was isolated from nasopharyngeal swabs collected from children who were younger than 7 years and had AOM, nonspecific upper respiratory infection, cough, acute sinusitis, or pharyngitis. Children were excluded from the study when they had received an antibiotic in the previous 4-week period.

Parents and providers completed a brief questionnaire to assess risk factors for carriage of NSSP. On the basis of National Clinical Chemistry Laboratory Standards, isolates with a penicillin minimum inhibitory concentration ≥ 0. 12 μg/mL were considered to be nonsusceptible to penicillin, and isolates with a penicillin minimum inhibitory concentration > 2 μg/mL were categorized as nonsusceptible to standard-dose amoxicillin. Results. S pneumoniae was isolated from the nasopharynx of 85 of 212 study patients; 41 of 85 isolates were NSSP, and 6 were NSSP-A. Conclusions. In our community, although the prevalence of NSSP among isolates of S pneumoniae identified from the nasopharynx of symptomatic children is high, the probability of NSSP-A infection among symptomatic children is < 5%.

Our data support a recommendation to treat most children who have uncomplicated AOM with standard-dose amoxicillin. Children who attend child care or have recently received an antibiotic may require treatment with high-dose amoxicillin. Other communities may benefit from a similar assessment of the prevalence of NSSP and NSSP-A. Comments.